UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended ~~March~~June 3130, 2016 Commission file number 333-184233-14

ACELITY L.P. INC.

(Exact name of registrant as specified in its charter)



Guernsey		98-1022387
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

12930 West Interstate 10 San Antonio, Texas		78249
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code: (210) 524-9000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.



Yes	X	No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).



Yes	X	No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer			Accelerated filer

Non-accelerated filer	X	(Do not check if a smaller reporting company)	Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).



Yes	No	X

As of ~~May~~August 21, 2016, there were 341,410,891.610 Class A-1 and 717,038.800 Class A-2 partnership units outstanding, all of which were held by affiliates.

TABLE OF CONTENTS

ACELITY L.P. INC.

			Page No.
PART I.	FINANCIAL INFORMATION		4
	Item 1.	Financial Statements	4
		Condensed Consolidated Balance Sheets	4
		Condensed Consolidated Statements of Operations	5
		Condensed Consolidated Statements of Comprehensive Loss	6
		Condensed Consolidated Statements of Cash Flows	7
		Notes to Condensed Consolidated Financial Statements	8
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	2932
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	4146
	Item 4.	Controls and Procedures	4146
PART II.	OTHER INFORMATION		4146
	Item 1.	Legal Proceedings	4146
	Item 1A.	Risk Factors	4146
	Item 6.	Exhibits	4247
	SIGNATURES		4348

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q includes statements that express our opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements.” The forward-looking statements are based on our current expectations and projections about future events. Discussions containing forward-looking statements may be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Risk Factors,” and elsewhere in this report. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “predicts,” “projects,” “potential,” “continue,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” or the negative of those terms and other variations of them or by comparable terminology.

These forward-looking statements are only predictions, not historical facts, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. The factors that could contribute to such differences include those discussed under the caption “Risk Factors.” You should consider each of the risk factors and uncertainties under the caption “Risk Factors” in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, among other things, in evaluating our prospects and future financial performance. The occurrence of the events described in the risk factors could harm our business, results of operations and financial condition. These forward-looking statements are made as of the date of this report. Except as required under federal securities laws and the rules and regulations of the SEC, we do not have any intention to update any forward-looking statements to reflect events or circumstances arising after the date of this report, whether as a result of new information, future events or otherwise.

TRADEMARKS, SERVICE MARKS AND COPYRIGHTS

We own a number of registered and common law trademarks and pending applications for trademark registrations in the United States and other countries, primarily through our subsidiaries (including KCI Licensing, Inc., LifeCell and Systagenix Wound Management IP Co B.V.), including: ABThera Open Abdomen Negative Pressure Therapy, AlloDerm Regenerative Tissue Matrix, AlloDerm RTU Regenerative Tissue Matrix, Strattice Reconstructive Tissue Matrix, Revolve System, Prevena Incision Management System, PROMOGRAN Matrix Wound Dressing, TIELLE Hydropolymer Adhesive Dressing, ADAPTIC Non-Adhering Dressing, V.A.C. Therapy, V.A.C. GranuFoam Dressing, CelluTome Epidermal Harvesting System, ~~SNaP~~SNAP Therapy System and iOn Healing Mobile App. Unless otherwise indicated, all trademarks appearing in this Quarterly Report on Form 10-Q are proprietary to us, our affiliates and/or licensors. This Quarterly Report on Form 10-Q also contains trademarks, trade names and service marks of other companies, which to our knowledge are the property of their respective owners. For example, 3M Tegaderm is a licensed trademark of 3M Company; GRAFTJACKET is a licensed trademark of Wright Medical Technology Inc.; and Prontosan Wound Irrigation Solution is a licensed trademark of B. Braun Medical, Inc. Solely for convenience, the trademarks, tradenames and service marks referred to in this Quarterly Report on Form 10-Q may appear without the ®, ™ and SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

DEFINED TERMS

The following terms are used in this Quarterly Report on Form 10-Q unless otherwise noted or indicated by the context.


•	“Acelity,” the “Company,” “we,” “us” and “our” mean Acelity L.P. Inc. and its consolidated subsidiaries;


•	The “2011 LBO” means the acquisition of KCI, LifeCell and their respective subsidiaries by the Sponsors and the corporate reorganization which resulted in LifeCell Corporation, formerly a 100% owned subsidiary of Kinetic Concepts, Inc., becoming a sister corporation of Kinetic Concepts, Inc., which was completed on November 4, 2011;


•	the term “KCI” means Kinetic Concepts, Inc. and its subsidiaries.


•	the term “LifeCell” means LifeCell Corporation and its subsidiaries.


•	the term “Systagenix” means “Systagenix Wound Management B.V., its subsidiaries, and its former U.S.-based affiliate, Systagenix Wound Management (US), Inc.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ACELITY L.P. INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands)

	March 31, 2016			December 31, 2015
	June 30, 2016			December 31, 2015
	(unaudited)
Assets:
Current assets:
Cash and cash equivalents	$	~~223~~99,~~616~~197		$	88,409
Accounts receivable, net	~~419~~413,~~883~~440			413,531
Inventories, net	~~188~~197,~~800~~583			181,309
Deferred income taxes	4351,~~781~~968			74,521
Prepaid expenses and other	2940,~~864~~117			34,985
Total current assets	~~905~~802,~~944~~305			792,755
Net property, plant and equipment	~~266~~260,~~008~~569			273,076
Deferred income taxes	2422,~~262~~333			29,909
Goodwill	3,406,475			3,405,823
Identifiable intangible assets, net	2,~~178~~139,~~864~~366			2,219,088
Other non-current assets	45,~~647~~033			6,104
	$	6,~~786~~636,~~200~~081		$	6,726,755
Liabilities and Equity:
Current liabilities:
Accounts payable	$	52,~~666~~718		$	57,910
Accrued expenses and other	~~420~~326,~~204~~302			373,440
Current installments of long-term debt	2223,~~258~~307			22,130
Income taxes payable	84,~~837~~372			3,561
Deferred income taxes	113,595			113,595
Total current liabilities	~~617~~520,~~560~~294			570,636
Long-term debt, net of current installments, discount and debt issuance costs	4,820,113			4,720,363
Long-term debt, net of current installments, premium, discount and debt issuance costs	4,845,783			4,720,363
Non-current tax liabilities	3334,~~694~~533			34,833
Deferred income taxes	~~698~~681,~~471~~592			760,737
Other non-current liabilities	3415,~~609~~153			37,021
Total liabilities	6,~~204~~097,~~447~~355			6,123,590
Equity:
General partner’s capital	—			—
Limited partners’ capital	~~597~~577,~~389~~979			622,899
Accumulated other comprehensive loss, net	(1539,~~636~~253		)	(19,734		)
Total equity	~~581~~538,~~753~~726			603,165
	$	6,~~786~~636,~~200~~081		$	6,726,755

See accompanying notes to condensed consolidated financial statements.

ACELITY L.P. INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(in thousands)

(unaudited)

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Revenue:
Rental	$	~~170~~175,~~099~~422		$	~~172~~180,~~839~~397		$	345,521		$	353,236
Sales	~~281~~296,~~267~~999			~~271~~281,~~211~~248			578,266			552,459
Total revenue	~~451~~472,~~366~~421			~~444~~461,~~050~~645			923,787			905,695
Rental expenses	7475,~~895~~794			7877,~~178~~869			150,689			156,047
Cost of sales	78,~~579~~118			7375,~~414~~509			156,697			148,923
Gross profit	~~297~~318,~~892~~509			~~292~~308,~~458~~267			616,401			600,725
Selling, general and administrative expenses	~~164~~182,~~444~~194			~~147~~158,~~763~~994			346,638			306,757
Research and development expenses	1314,~~978~~717			14,~~678~~391			28,695			29,069
Acquired intangible asset amortization	4241,~~202~~159			4544,~~877~~712			83,361			90,589
Operating earnings	7780,~~268~~439			8490,~~140~~170			157,707			174,310
Interest income and other	~~107~~589			~~147~~67			696			214
Interest expense	(~~108~~110,~~552~~428		)	(~~104~~107,~~726~~374		)	(218,980		)	(212,100		)
Loss on extinguishment of debt	(310,~~609~~107		)	—			(13,716		)	—
Foreign currency gain (loss)	(48,~~330~~998		)	19(6,~~400~~799		)	4,668			12,601
Derivative instruments loss	(~~682~~357		)	(~~3,348~~919		)	(1,039		)	(4,267		)
Loss before income tax expense (benefit)	(39,798		)	(4,387		)
Loss before income tax benefit	(30,866		)	(24,855		)	(70,664		)	(29,242		)
Income tax expense (benefit)	(13,823		)	144
Income tax benefit	(10,751		)	(7,224		)	(24,574		)	(7,080		)
Net loss	$	(2520,~~975~~115	)	$	(417,~~531~~631	)	$	(46,090	)	$	(22,162	)

See accompanying notes to condensed consolidated financial statements.

ACELITY L.P. INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(in thousands)

(unaudited)

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Net loss	$	(2520,~~975~~115	)	$	(417,~~531~~631	)	$	(46,090	)	$	(22,162	)
Foreign currency translation adjustment, net of tax benefit (expense) of $755 in 2016 and ($635) in 2015	4,098			(7,071		)
Foreign currency translation adjustment, net of tax benefit (expense) of $584 and $1,339 in 2016 and ($317) and ($952) in 2015	(12,324		)	4,935			(8,226		)	(2,136		)
Total comprehensive loss	$	(21,877	)	$	(11,602	)
Net derivative loss, net of taxes of $0	(11,293		)	—			(11,293		)	—
Total comprehensive loss	$	(43,732	)	$	(12,696	)	$	(65,609	)	$	(24,298	)

See accompanying notes to condensed consolidated financial statements.

ACELITY L.P. INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(in thousands)(unaudited)
	Three months ended March 31,
	Six months ended June 30,
	2016			2015
Cash flows from operating activities:
Net loss	$	(2546,~~975~~090	)	$	(422,~~531~~162	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Adjustments to reconcile net loss to net cash used by operating activities:
Amortization of debt issuance costs and discount	10,107			9,968
Amortization of debt issuance costs, premium and discount	19,352			20,311
Depreciation and other amortization	64127,~~734~~418			66132,~~331~~334
Loss on disposition of assets	~~576~~1,122			~~678~~1,265
Amortization of fair value step-up in inventory	164			—
Provision for bad debt	23,~~183~~429			13,~~827~~266
Loss on extinguishment of debt	313,~~609~~716			—
Equity-based compensation expense	~~768~~1,602			~~535~~1,305
Deferred income tax benefit	(2446,~~076~~880		)	(1130,~~971~~224		)
Unrealized gain on derivative instruments	(25,~~812~~944		)	(~~315~~3,078		)
Unrealized loss (gain) on foreign currency	5,327			(32,429		)
Unrealized gain on foreign currency	(7,147		)	(16,683		)
Change in assets and liabilities:
Decrease (increase) in accounts receivable, net	(7,694		)	5,362
Increase in accounts receivable, net	(7,500		)	(968		)
Increase in inventories, net	(~~416~~5,656		)	(310,~~666~~856		)
Decrease (increase) in prepaid expenses and other	5,121			(774		)
Increase in prepaid expenses and other	(5,133		)	(4,685		)
Increase (decrease) in accounts payable	(5,183		)	4,363
Decrease in accounts payable	(5,543		)	(3,533		)
Increase in accrued expenses and other	49,438			56,048
Decrease in accrued expenses and other	(74,994		)	(76,509		)
Increase (decrease) in tax liabilities, net	2(1,~~314~~495		)	116,~~525~~213
Net cash provided by operating activities	78,185			102,951
Net cash used by operating activities	(39,579		)	(4,004		)
Cash flows from investing activities:
Additions to property, plant and equipment	(1735,~~467~~762		)	(1029,~~491~~574		)
Increase in inventory to be converted into equipment for short-term rental	(~~983~~98		)	(34,~~356~~144		)
Dispositions of property, plant and equipment	2			—
Increase in identifiable intangible assets and other non-current assets	(1,129		)	(1,821		)
Businesses acquired in purchase transactions, net of cash acquired	—			(2,948		)
Net cash used by investing activities	(19,577		)	(15,668		)
Increase in identifiable intangible assets and other non-current assets	(3,684		)	(3,646		)
Net cash used by investing activities	(39,542		)	(40,312		)
Cash flows from financing activities:
Distribution to limited partners	—			(55		)
Settlement of profits interest units	(217		)	(517		)
Settlement of equity-based awards	(226		)	(1,348		)
Proceeds from first lien senior secured notes	400,000			—
Proceeds from revolving credit facility	25,000			30,000
Repayments of long-term debt and capital lease obligations	(317,731		)	(6,415		)
Proceeds from debt issuance	595,044			—
Debt issuance costs	(8,407		)	(6,256		)
Repayments of long-term debt and capital lease obligations	(518,570		)	(15,389		)
Net cash provided (used) by financing activities	73,645			(13,243		)
Debt issuance costs	(12,899		)	(6,256		)
Effect of exchange rate changes on cash and cash equivalents	2,954			(7,072		)
Net cash provided by financing activities	88,349			6,952
Net increase in cash and cash equivalents	135,207			66,968
Effect of exchange rate changes on cash and cash equivalents	1,560			(5,025		)
Net increase (decrease) in cash and cash equivalents	10,788			(42,389		)
Cash and cash equivalents, beginning of period	88,409			183,541
Cash and cash equivalents, end of period	$	~~223~~99,~~616~~197		$	~~250~~141,~~509~~152

See accompanying notes to condensed consolidated financial statements

Notes to Condensed Consolidated Financial Statements

NOTE 1. Summary of Significant Accounting Policies

(a) Basis of Presentation and Principles of Consolidation

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP” or “the Codification”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, financial position and cash flows in conformity with GAAP. Operating results from interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation of our results for the interim periods presented. Certain prior period amounts have been reclassified to conform to the 2016 presentation.

The Company has two reportable operating segments: Advanced Wound Therapeutics and Regenerative Medicine. We also have other revenue which consists of contract manufacturing operations performed at our manufacturing facility in Gargrave, England.

The condensed consolidated financial statements appearing in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

(b) Derivative Financial Instruments and Fair Value Measurements

We use derivative financial instruments to manage the economic impact of fluctuations in interest rates. We do not use financial instruments for speculative or trading purposes. Periodically, we enter into interest rate protection agreements to modify the interest characteristics of our outstanding debt. As of ~~March~~June 3130, 2016, ~~our~~we have three interest rate derivatives that have not been designated as hedging instruments, and three interest rate derivatives that have been designated as ~~such~~cash flow hedge instruments. For our interest rate derivatives that have not been designated as hedging instruments, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period. For our cash flow hedge instruments which begin in December 2016 and extend through December 2021, changes in the fair value are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction as long as the derivative is highly effective. At inception, all derivatives are expected to be highly effective. Each interest rate swap is designated as a hedge of interest payments associated with specific principal balances and terms of our debt obligations. These agreements involve the exchange of amounts based on variable interest rates, for amounts based on fixed interest rates over the life of the agreement, without an exchange of the notional amount upon which the payments are based.

We also periodically use derivative financial instruments to manage the economic impact of fluctuations in currency exchange rates on our intercompany balances and corresponding cash flows and to manage our transactional currency exposures when our foreign subsidiaries enter into transactions denominated in currencies other than their local currency. We enter into foreign currency exchange contracts to manage these economic risks. These contracts are not designated as hedges; and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period. Although we use master netting agreements with our derivative counterparties, we do not offset derivative asset and liability positions in the condensed consolidated balance sheets.

All derivative instruments are recorded on the balance sheets at fair value. The fair values of our interest rate derivatives and foreign currency exchange contracts are determined based on inputs that are readily available in public markets or can be derived from information available in publicly-quoted markets, which represent level 2 inputs as defined by the Codification.

We have a concentration of credit risk with financial institutions related to our derivative instruments. As of ~~March~~June 3130, 2016, Morgan Stanley, UBS and HSBC were the counterparties on our interest rate protection agreements consisting of interest rate swap agreements not designated as hedging instruments in notional amounts totaling $~~459~~458.37 million each. UBS, Nomura and Goldman Sachs were counterparties on our interest rate protection agreements, which become effective in December 2016, consisting of interest rate swap agreements that have been designated as cash flow hedge instruments in notional amounts totaling $291.2 million, $291.2 million and $582.5 million, respectively. We use master netting agreements with our derivative counterparties to reduce our risk and use multiple counterparties to reduce our concentration of credit risk.

We maintain cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits bear minimal credit risk as they are maintained at financial institutions of reputable credit and generally may be redeemed upon demand.

(d) Recently Adopted Accounting Standards

In January 2015, the Financial Accounting Standard Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-01, "Income Statement -Extraordinary and Unusual Items (Subtopic 225-20)." The objective of this ASU is to simplify the income statement presentation requirements in Subtopic 225-20 by eliminating the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The Company adopted this ASU effective January 1, 2016. The adoption of this update did not have a material impact on our results of operations, financial position or disclosures.

On February 18, 2015, the FASB issued ASU 2015-02, "Consolidation (Topic 810): Amendments to the Consolidation Analysis." This update provides a revised consolidation model for all reporting entities to use in evaluating whether they should consolidate certain legal entities. All legal entities will be subject to reevaluation under this revised consolidation model. The revised consolidation model, among other things, (i) modifies the evaluation of whether limited partnerships and similar legal entities are variable interest entities ("VIEs") or voting interest entities, (ii) eliminates the presumption that a general partner should consolidate a limited partnership, and (iii) modifies the consolidation analysis of reporting entities that are involved with VIEs through fee arrangements and related party relationships. The Company adopted this ASU effective January 1, 2016. The adoption of this update did not have a material impact on our results of operations, financial position or disclosures.

In April 2015, the FASB issued ASU 2015-03, "Interest - Imputation of Interest (Subtopic 835-30)." The objective of this ASU was to simplify the presentation of debt issuance costs in the balance sheet by requiring the presentation of debt issuance costs as a deduction from the carrying amount of the related debt liability instead of a deferred charge. Prior to the issuance of ASU 2015-03, debt issuance costs were required to be presented as an asset in the balance sheet. The Company adopted this ASU effective January 1, 2016, resulting in a $54.7 million retrospective reduction of both our non-current assets and long-term debt, net of current installments, discount and debt issuance costs, as of December 31, 2015.

In September 2015, the FASB issued ASU 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments.” The amendments in this ASU require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments in this ASU also require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. Additionally, the amendments in this ASU require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. The Company adopted this ASU effective January 1, 2016. The adoption of this update did not have a material impact on our results of operations, financial position or disclosures.

(e) Recently Issued Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” This ASU affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU supersedes the revenue recognition requirements in Topic 605, “Revenue Recognition”, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, “Revenue Recognition-Construction-Type and Production-Type Contracts”. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, “Property, Plant, and Equipment”, and intangible assets within the scope of Topic 350, “Intangibles-Goodwill and Other”) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. For a public entity, the

nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, “Property, Plant, and Equipment”, and intangible assets within the scope of Topic 350, “Intangibles-Goodwill and Other”) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The standard may be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company has not selected a transition method and we are evaluating ASU No. 2014-09 to determine if it will have a material effect on our results of operations, financial position or disclosures.

In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements — Going Concern (Subtopic 205-40).” The new guidance addresses management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. Management’s evaluation should be based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In July 2015, the FASB issued ASU 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory.” The amendments in this ASU do not apply to inventory that is measured using last-in, first-out or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost. An entity should measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating this ASU, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes,” which changes how deferred taxes are classified on organizations’ balance sheets. The ASU eliminates the current requirement for organizations to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, organizations will be required to classify all deferred tax assets and liabilities as noncurrent. The amendments apply to all organizations that present a classified balance sheet. The standard will be effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods.

In January 2016, the FASB issued ASU 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” This ASU amends existing guidance related to the recognition, measurement, presentation, and disclosure of financial instruments. The ASU eliminates the existing requirement to disclose the methods and significant assumptions used to estimate the fair value required to be disclosed for financial instruments measured at amortized cost on the balance sheet, instead requiring entities to disclose the fair value of these financial instruments using the exit price. This ASU also requires an entity that elects to measure a liability at fair value to present separately in other comprehensive income the portion of the total change in the liability’s fair value that is due to a change in credit risk specifically related to the financial instrument. Additionally, this ASU requires that financial assets and financial liabilities be presented separately by measurement category and form of financial asset on the balance sheet or in the notes to the financial statements. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2017. Early adoption is only permitted for separate presentation in other comprehensive income as of the beginning of the fiscal year of adoption. The standard should be applied by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842).” The objective of this ASU is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and increasing disclosure requirements to include key information about leasing arrangements. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. When measuring assets and liabilities arising from a lease, a lessee should include payments to be made in optional periods, and optional payments to purchase, only if the lessee is reasonably certain to exercise the option. This new guidance continues to differentiate between finance leases and operating leases; there have been no significant changes in the recognition, measurement, and presentation of expenses and cash flows. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The standard must be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is evaluating this update.

In March 2016, the FASB issued ASU 2016-06, “Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments,” which applies to all entities that are issuers of or investors in debt instruments (or hybrid financial instruments that are determined to have a debt host) with embedded call (put) options. This amendment requires an entity to assess the embedded call (put) options solely in accordance with the four-step decision sequence. Additionally, this ASU clarifies the requirements for assessing whether contingent call (put) options that can accelerate the payment of principal on debt instruments are clearly and closely related to their debt hosts, which is one of the criteria for bifurcating an embedded derivative. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted, including in an interim period. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The standard should be applied on a modified retrospective basis to existing debt instruments as of the beginning of the fiscal year for which the amendments are effective. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net).” When another party is involved in providing goods or services to a customer, this ASU provides additional guidance for entities in determining whether the nature of its promise is to provide that good or service to the customer (i.e. the entity is the principal) or to arrange for the good or service to be provided to the customer by the other party (i.e., the entity is the agent). This amendment clarifies that an entity determine whether it is a principal or an agent for each specified good or service promised to a customer and determine the nature of each specified good or service. The effective date and transition for this ASU is the same as ASU 2014-09. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” The amendment in this ASU affects all organizations that issue share-based payment awards to employees and is intended to simplify several aspects of the accounting for these awards, including income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and allowing an accounting policy election to account for forfeitures as they occur. This standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2016. Early adoption is permitted, however an entity must adopt all of the amendments in the same period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes the interim period. Transition guidance is dependent on the individual amendment within the update. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing.” This standard clarifies the guidance in ASU 2014-09 for entities in identifying performance obligations, and the licensing implementation guidance. The ASU clarifies that an entity is not required to assess whether promised goods or services are performance obligations if they are immaterial to the contract. This update also allows entities to make a policy election to account for shipping and handling occurring after the customer has obtained control of a good as an activity to fulfill the promise to transfer the good rather than an additional promise. Additionally, the update includes clarification on whether an entity’s promise to grant a customer a license to intellectual property that has a significant standalone functionality or symbolic intellectual property, that does not have significant standalone functionality, include support during the license period. The effective date and transition for this ASU is the same as ASU 2014-09. The Company is evaluating this update, however we do not anticipate that the adoption of this guidance will have a material impact on our results of operations, financial position or disclosures.

(f) Other Significant Accounting Policies

For further information on our significant accounting policies, see Note 1 of the notes to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

NOTE 2. Acquisitions and Divestitures

Acquisitions

Spiracur Inc.

On December 1, 2015, we closed the acquisition of the ~~SNaP~~SNAP business from Spiracur Inc., expanding our offering in disposable, portable, mechanical negative pressure wound therapy ("NPWT") technology, and allowing our sales and service channels to accelerate the expansion of the ~~SNaP~~SNAP Therapy System to patients and their care teams around the world who need access to NPWT devices. The aggregate purchase price of this acquisition was $42.5 million, all of which was paid in cash. The allocation of the purchase price to the tangible and identifiable intangible assets was based on their estimated fair values as of the acquisition date using the income approach. The excess of the purchase price over the identifiable intangible and net tangible assets was allocated to goodwill, which is not deductible for tax purposes. Goodwill recognized was primarily attributable to potential operational synergies related to overhead cost reductions. The purchase price allocation is preliminary, pending the final determination of the fair value of certain assumed assets and liabilities. As these issues are identified, modified or resolved, resulting increases or decreases to the preliminary value of assets and liabilities are offset by a change to goodwill. Adjustments to these estimates will be included in the final allocation of the purchase price.

The consolidated financial statements include the results of operations from this business combination from the date of the acquisition. Had the transaction occurred at the beginning of fiscal 2015, consolidated results of operations would not have differed materially from reported results.

The following table represents the preliminary allocation of the purchase price ($ in thousands):

	December 31, 2015			Adjustments			~~March~~June 3130, 2016
Goodwill	$	27,525		$	652		$	28,177
Identifiable intangible assets:
Customer relationships	5,800						5,800
Developed technology	6,400						6,400
Tradenames	2,400						2,400
Tangible assets acquired and liabilities assumed:
Inventories	1,741						1,741
Other current assets	125						125
Property, plant and equipment	250						250
Current liabilities	(713		)	(1,639		)	(2,352		)
Other non-current liabilities	(987		)	987			—
Total purchase price	$	42,541		$	—		$	42,541

Purchase accounting rules require that as certain pre-acquisition issues are identified, modified or resolved, resulting increases or decreases to the preliminary value of assets and liabilities are offset by a change in goodwill. Modifications to goodwill reflected in the “Adjustments” column above were primarily the result of assumed liabilities.

Divestitures

There were no divestitures during the ~~three~~six months ended ~~March~~June 3130, 2016.

NOTE 3. Supplemental Balance Sheet Data

(a) Accounts Receivable, net

Accounts receivable consist of the following (in thousands):

	March 31, 2016			December 31, 2015
	June 30, 2016			December 31, 2015
Gross trade accounts receivable:
Billed trade accounts receivable	$	~~440~~436,~~710~~388		$	429,556
Unbilled receivables	4240,~~032~~212			48,795
Less: Allowance for revenue adjustments	(6263,~~767~~708		)	(66,868		)
Gross trade accounts receivable	~~419~~412,~~975~~892			411,483
Less: Allowance for bad debt	(1211,~~425~~485		)	(11,372		)
Net trade accounts receivable	~~407~~401,~~550~~407			400,111
Other receivables	12,~~333~~033			13,420
	$	~~419~~413,~~883~~440		$	413,531

(b) Inventories, net

Inventories consist of the following (in thousands):

	March 31, 2016			December 31, 2015
	June 30, 2016			December 31, 2015
Finished goods and tissue available for distribution	$	~~139~~142,~~589~~877		$	133,293
Goods and tissue in-process	13,~~677~~239			9,778
Raw materials, supplies, parts and unprocessed tissue	6569,~~767~~037			67,433
	219,033			210,504
	225,153			210,504
Less: Amounts expected to be converted into equipment for short-term rental	(109,~~580~~695		)	(9,597		)
Reserve for excess and obsolete inventory	(1917,~~653~~875		)	(19,598		)
	$	~~188~~197,~~800~~583		$	181,309

NOTE 4. Long-Term Debt

Long-term debt consists of the following (in thousands):

	March 31, 2016			December 31, 2015
	June 30, 2016			December 31, 2015
Senior Dollar Term E-1 Credit Facility – due 2018	$	1,902,907		$	1,907,774
Senior Revolving Credit Facility - due 2017(1)	$	25,000		$	—
Senior Euro Term E-1 Credit Facility – due 2018	272,784			260,946
Senior Dollar Term F Credit Facility – due 2020(2)	1,702,733			1,907,774
Senior Term E-2 Credit Facility – due 2016 (1)	—			312,166
Senior Euro Term F Credit Facility – due 2020(2)	264,647			260,946
Senior Term E-2 Credit Facility – due 2016 (3)	—			312,166
10.5% Second Lien Senior Secured Notes due 2018	1,750,000			1,750,000
12.5% Senior Unsecured Notes due 2019	612,000			612,000
7.875% First Lien Senior Secured Notes due 2021	~~400~~590,000			—
Notional amount of debt	4,~~937~~944,~~691~~380			4,842,886
Senior Dollar Term E-1 Credit Facility Discount, net of accretion	(18,670		)	(20,792		)
Senior Dollar Term F Credit Facility Discount, net of accretion(2)	(16,686		)	(20,792		)
Senior Euro Term E-1 Credit Facility Discount, net of accretion	(4,919		)	(5,224		)
Senior Euro Term F Credit Facility Discount, net of accretion(2)	(4,946		)	(5,224		)
Senior Term E-2 Credit Facility Discount, net of accretion	—			(1,770		)
Senior Term E-2 Credit Facility Discount, net of accretion(3)	—			(1,770		)
Second Lien Senior Secured Notes Discount, net of accretion	(1413,~~533~~303		)	(15,729		)
Senior Unsecured Notes Discount, net of accretion	(21,~~113~~995		)	(2,227		)
Net discount on debt	(40,235		)	(45,742		)
First Lien Senior Secured Notes Premium, net of amortization	9,934			—
Net debt issuance costs	(55,085		)	(54,651		)
Net discount on debt	(26,996		)	(45,742		)
Total debt, net of discount and debt issuance costs	4,842,371			4,742,493
Net debt issuance costs	(48,294		)	(54,651		)
Less: Current installments	(22,258		)	(22,130		)
Total debt, net of premium, discount and debt issuance costs	4,869,090			4,742,493
	$	4,820,113		$	4,720,363
Less: Current installments	(23,307		)	(22,130		)
	$	4,845,783		$	4,720,363

(1) ~~All~~On ~~amounts~~February ~~outstanding~~9, ~~under~~2016 ~~the~~we ~~Senior~~entered ~~Term~~into ~~E-2~~Amendment No. 7 and Amendment No. 8 to our senior secured credit facilities. As a result of these amendments, we have aggregate revolving loan commitments under our Revolving Credit Facility ~~were~~of ~~paid~~$171.3 inmillion ~~full~~maturing on ~~February~~November 94, ~~2016~~2017, with ~~proceeds~~an ~~from~~additional ~~the~~$28.7 ~~offering~~million ofin ~~the~~revolving ~~7.875%~~loan ~~First~~commitments ~~Lien~~continuing ~~Senior~~to ~~Secured~~mature ~~Notes~~on ~~due~~November ~~2021~~4, 2016.


(2)	On June 16, 2016, we entered into Amendment No. 9 to our senior secured credit facilities. As a result of the amendment we created new classes of Dollar Term F Loans and Euro Term F Loans, having the same rights and obligations as the Dollar Term E-1 Loans and Euro Term E-1 Loans as set forth in the credit agreement and loan documents, except as revised by the amendment.


(3)	All amounts outstanding under the Senior Term E-2 Credit Facility were paid in full on February 9, 2016, with proceeds from the offering of the 7.875% First Lien Senior Secured Notes due 2021.

Senior Secured Credit Facilities

Our senior secured credit facilities (the “Senior Secured Credit Facilities”) ~~includes~~include a $200 million revolving credit facility (the “Revolving Credit Facility”). Amounts available under the Revolving Credit Facility are available for borrowing and reborrowing until maturity. At ~~March~~June 3130, 2016, $25.0 ~~and~~million revolving credit loans were outstanding, while at December 31, 2015, no revolving credit loans were outstanding and we had outstanding letters of credit issued by banks which are party to the Senior Secured Credit Facilities of $3736.96 million and $38.2 million, respectively. The $25.0 million borrowing under the Revolving Credit Facility was repaid in July 2016 using cash from operations. In addition, we had $75.78 million and $8.5 million of letters of credit issued by a bank not party to the Senior Secured Credit Facilities as of ~~March~~June 3130, 2016, and December 31, 2015, respectively. The capacity of the Revolving Credit Facility is reduced for the $3736.96 million and $38.2 million of letters of credit issued by banks which are party to the Senior Secured Credit Facilities as of ~~March~~June 3130, 2016, and December 31, 2015, respectively. The resulting availability under the Revolving Credit Facility was $~~162~~138.14 million and $161.8 million at ~~March~~June 3130, 2016, and December 31, 2015, respectively. Commitment fees accrue at a rate of 0.50% on the amounts available under the Revolving Credit Facility.

On February 9, 2016, we entered into Amendment No. 7 to the Senior Secured Credit Facilities ("Amendment No. 7"). Pursuant to Amendment No. 7, among other things, the maturity date of certain consenting lenders’ commitments under the Revolving Credit Facility was extended to November 4, 2017. Promptly after the effectiveness of Amendment No. 7, we permanently reduced, or the Permanent Reduction, a portion of the commitments under our Revolving Credit Facility of lenders that did not consent to extend the maturity date of their commitments under the Revolving Credit Facility pursuant to Amendment No. 7. On February 9, 2016, we also entered into Amendment No. 8 to the Senior Secured Credit Facilities. In connection with Amendment No. 8, certain lenders agreed to provide incremental commitments under the Revolving Credit Facility in a principal amount equal to the principal amount of the commitments subject to the Permanent Reduction, and such incremental commitments also have a maturity date of November 4, 2017. After giving effect to Amendment No. 7 and Amendment No. 8, we have aggregate revolving loan commitments under our Revolving Credit Facility of $171.3 million maturing on November 4, 2017, with an additional $28.7 million in revolving loan commitments continuing to mature on November 4, 2016.

reduced, or the Permanent Reduction, a portion of the commitments under our Revolving Credit Facility of lenders that did not consent to extend the maturity date of their commitments under the Revolving Credit Facility pursuant to Amendment No. 7. On February 9, 2016, we also entered into Amendment No. 8 to the Senior Secured Credit Facilities ("Amendment No. 8"). In connection with Amendment No. 8, certain lenders agreed to provide incremental commitments under the Revolving Credit Facility in a principal amount equal to the principal amount of the commitments subject to the Permanent Reduction, and such incremental commitments also have a maturity date of November 4, 2017. After giving effect to Amendment No. 7 and Amendment No. 8, we have aggregate revolving loan commitments under our Revolving Credit Facility of $171.3 million maturing on November 4, 2017, with an additional $28.7 million in revolving loan commitments continuing to mature on November 4, 2016.

On June 16, 2016, we entered into Amendment No. 9 to our Senior Secured Credit Facility (“Amendment No. 9”). In connection with Amendment No. 9, we created new classes of Dollar Term F Loans and Euro Term F Loans, having the same rights and obligations as the Dollar Term E-1 Loans and Euro Term E-1 Loans as set forth in the Senior Secured Credit Facilities, except as revised by Amendment No. 9. Lenders exchanged $1.707 billion of Dollar Term E-1 Loans and all Euro Term E-1 Loans for equivalent amounts of Dollar F Loans and Euro Term F Loans, respectively. The Dollar Term F Loans and Euro Term F Loans mature on November 4, 2020. Applicable rates were modified so that (i) Dollar Term F Loans bear interest at a rate equal to, at KCI’s election, a Eurocurrency rate plus 4.00% or an adjusted base rate plus 3.00%, and (ii) Euro Term F Loans bear interest at a rate equal to, at KCI’s election, a Eurocurrency rate plus 4.00% or an adjusted base rate plus 3.00%. The Eurocurrency rate shall be subject to a floor of 1.00%, and the adjusted base rate shall be subject to a floor of 2.00%.

7.875% First Lien Senior Secured Notes

OnIn ~~February 9,~~ 2016, Kinetic Concepts, Inc. and KCI USA, Inc., each a wholly-owned subsidiary of Acelity L.P. Inc. (together, the "Notes Issuers"), co-issued 7.875% First Lien ~~Notes~~Senior ~~Issuers~~Secured notes due 2021 (the "First Lien Notes"). On February 9, 2016, the Notes Issuers, co-issued $400.0 million aggregate principal amount of ~~7.875%~~ First Lien Senior Secured notes ~~due~~and ~~2021~~used (the "net proceeds to pay in full all amounts outstanding under the Senior Term E-2 Credit Facility. On June 22, 2016, the Notes Issuers co-issued an additional $190.0 million aggregate principal amount of First Lien Notes") and used the net proceeds to pay in full all Dollar Term E-1 Loans that were not exchanged in connection with Amendment No. 9.

Interest. Interest on the First Lien Notes accrues at the rate of 7.875% per annum and is payable semiannually in arrears on each February 15 and August 15, beginning on August 15, 2016. Interest is computed on the basis of a 360-day year consisting of twelve 30-day months.

Collateral. The First Lien Notes are secured on a first priority basis by a perfected security interest in substantially all of the ~~First Lien~~ Notes Issuers' and the guarantors' tangible and intangible assets (subject to certain exceptions), including U.S. registered intellectual property and all of the capital stock of each of Acelity L.P. Inc.'s direct and indirect wholly-owned material restricted subsidiaries, including the ~~First Lien~~ Notes Issuers (limited, in the case of foreign subsidiaries and domestic foreign holding companies, to 65% of the voting capital stock of material foreign subsidiaries and domestic foreign holding companies). The liens securing the ~~first~~First ~~lien~~Lien ~~notes~~Notes are subject to permitted liens.

Guarantors. Our Notes Issuers' obligations under the First Lien Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis, by Acelity L.P. Inc., Chiron Topco, Inc., Chiron Holdings, Inc., LifeCell Corporation and each of Acelity L.P. Inc.’s other subsidiaries to the extent such entities guarantee indebtedness under the Senior Secured Credit Facilities or the 10.5% Second Lien Senior Secured Notes due 2018 (the "Second Lien Notes") and the 12.5% Senior Unsecured Notes due 2019 (together with the Second Lien Notes, the "Existing Notes").

Maturity. The First Lien Notes will mature on February 15, 2021.

Covenants. The indenture governing the First Lien Notes contains covenants customary for similar transactions, including limitations or restrictions on our ability to:


•	incur additional indebtedness and guarantee indebtedness;


•	pay dividends or make other distributions in respect of, or repurchase or redeem, capital stock;


•	prepay, redeem or repurchase certain debt;


•	make loans and investments;


•	sell or otherwise dispose of assets;


•	incur liens;


•	enter into transactions with affiliates;


•	enter into agreements restricting our subsidiaries’ ability to pay dividends; and


•	consolidate, merge or sell all or substantially all of our assets.

Optional Redemption. At any time prior to February 15, 2018, the ~~First Lien~~ Notes Issuers, at their option, may redeem up to 40% of the aggregate principal amount of the First Lien Notes with the net cash proceeds of certain equity offerings, at a redemption price equal to 107.875% of the aggregate principal amount of the First Lien Notes being redeemed plus accrued and unpaid interest, if any.

At any time prior to February 15, 2018, the ~~First Lien~~ Notes Issuers, at their option, may redeem all or part of the First Lien Notes at a redemption price equal to 100% of the aggregate principal amount of the First Lien Notes to be redeemed, plus a make-whole premium plus accrued and unpaid interest, if any, to the date of redemption.

At any time on or after February 15, 2018, the Notes Issuers may redeem the First Lien Notes, in whole or in part, at the following redemption prices (expressed as percentages of the principal amount) if redeemed during the twelve‑month period commencing on February 15 of the year set forth below, plus, in each case, accrued and unpaid interest thereon, if any, to the date of redemption:

At any time on or after February 15, 2018, the First Lien Notes Issuers may redeem the First Lien Notes, in whole or in part, at the following redemption prices (expressed as percentages of the principal amount) if redeemed during the twelve‑month period commencing on February 15 of the year set forth below, plus, in each case, accrued and unpaid interest thereon, if any, to the date of redemption:



Year		Price
2018		103.938%
2019		101.969%
2020 and thereafter		100.000%

Change of Control. If ~~First~~the ~~Lien~~ Notes Issuers experience certain kinds of changes of control specified in the indenture governing the First Lien Notes, the ~~First Lien~~ Notes Issuers will be required to offer to repurchase the First Lien Notes at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any.

Events of Default. The indenture governing the First Lien Notes contains events of default (subject in certain cases to customary grace and cure periods) including, but not limited to, failure to pay principal or interest, breach of covenants, payment defaults or acceleration of other indebtedness, a bankruptcy or similar proceeding being instituted by or against us, rendering of certain monetary judgments against us, and impairments of loan documentation or security.

Registration. The First Lien Notes and related guarantees have not been and will not be registered under the Securities Act of 1933, as amended, or the securities laws of any other jurisdiction.

Covenants

As of ~~March~~June 3130, 2016, we were in compliance with the covenants under the credit agreement governing our Senior Secured Credit Facilities and indentures governing the First Lien Notes and the Existing Notes.

For further information on our long-term debt, see Note 5 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

NOTE 5. Derivative Financial Instruments and Fair Value Measurements

We are exposed to credit loss in the event of nonperformance by counterparties to the extent of the fair values of the outstanding interest rate swap agreements, interest rate cap agreements and foreign currency exchange contracts, but we do not anticipate nonperformance by any of the counterparties. All derivative instruments are recorded on the balance sheets at fair value. We do not use financial instruments for speculative or trading purposes.

Interest Rate Protection

At ~~March~~June 3130, 2016 and December 31, 2015, we were party to three interest rate swap agreements which are used to convert a portion of our outstanding variable -rate debt to a fixed -rate basis. These agreements, which began in December 2013 and extend through December 2016, have not been designated as hedging instruments, and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period. The interest rate swap agreements have receive rates based on the higher of three-month USD LIBOR or 1.25% and pay rates based on fixed rates. Quarterly payments under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by amounts ranging from $1.7 million to $1.8 million until maturity.

The following table summarizes our interest rate swap agreements (dollars in thousands):

Effective Dates	Outstanding Notional Amount	Fixed Interest Rate
12/31/13-12/31/16	$459,333	2.256%
12/31/13-12/31/16	$459,333	2.249%
12/31/13-12/31/16	$459,333	2.250%

In April 2016, we entered into three additional interest rate swap agreements to convert $1.165 billion of our variable-rate debt to a fixed-rate basis, which become effective in December 2016. These agreements have been designated as cash flow

~~hedge instruments. Quarterly payments~~ under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by ~~amounts ranging from~~ $41.47 million ~~to $84.5 million~~ until maturity.

The following table summarizes our interest rate swap agreements which have not been designated as hedging instruments (dollars in thousands):



Outstanding Notional Amount		Fixed Interest Rate
$458,733		2.256%
$458,733		2.249%
$458,733		2.250%

In April 2016, we entered into three additional interest rate swap agreements to convert $1.165 billion of our variable-rate debt to a fixed-rate basis, which begin in December 2016 and extend through December 2021. These agreements have been designated as cash flow hedge instruments. Quarterly payments under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by amounts ranging from $4.4 million to $84.5 million until maturity.

The following table summarizes our interest rate swap agreements which have been designated as hedging instruments (dollars in thousands):



Outstanding Notional Amount		Fixed Interest Rate
$291,225		1.663%
$291,225		1.668%
$582,450		1.666%

Foreign Currency Exchange Rate Mitigation

At ~~March~~June 3130, 2016 and December 31, 2015, we had no outstanding foreign currency exchange contracts.

Fair Value Measurements

The Codification defines fair value as the exit price that would be received to sell an asset or paid to transfer a liability. The Fair Value Measurements and Disclosure topic of the Codification establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amount reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable and long-term obligations, excluding our borrowings under our Senior Secured Credit Facilities and fixed rate long-term debt, approximates fair value. The fair value of our borrowings under our Senior Secured Credit Facilities and fixed rate long-term debt was $21.~~164~~959 billion and $2.~~700~~946 billion, respectively, at ~~March~~June 3130, 2016. The fair value of our borrowings under our Senior Secured Credit Facilities and fixed rate long-term debt was $2.400 billion and $2.257 billion, respectively, at December 31, 2015. The fair value of our long-term debt was estimated based upon open-market trades at or near year end.

All of our derivatives, as of the reporting date, use inputs considered as Level 2. The interest rate swap agreements are valued using a discounted cash flow model that takes into account the present value of the expected future cash flows under the terms of the agreements by using market information available as of the reporting date, including prevailing interest rates and related forward interest rate curves.

The following table sets forth the location and aggregate fair value amounts of all derivative instruments with credit-related contingent features (in thousands):

	Asset Derivatives					Liability Derivatives
	BalanceSheetLocation	Fair Value				BalanceSheetLocation	Fair Value
		March 31, 2016		December 31, 2015			March 31, 2016		December 31, 2015
		June 30, 2016		December 31, 2015			June 30, 2016		December 31, 2015
Derivatives not designated as hedging instruments
Interest rate swap agreements	Prepaid expenses and other	$	—	$	—	Accrued expenses and other	$	96,~~431~~299	$	12,243
Interest rate swap agreements	Other non-current assets	—		—		Other non-current liabilities	—		—
Total derivatives		$	—	$	—		$	9,431	$	12,243
Derivatives designated as hedging instruments
Interest rate swap agreements	Prepaid expenses and other	—		—		Accrued expenses and other	3,557		—
Interest rate swap agreements	Other non-current assets	—		—		Other non-current liabilities	7,736		—
Total derivatives		$	—	$	—		$	17,592	$	12,243

The following table summarizes the amount of gain (loss) on derivatives not designated as hedging instruments (dollars in thousands):

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Interest rate swap agreements	$	(~~682~~357	)	$	(~~3,348~~919	)	$	(1,039	)	$	(4,267	)
Foreign currency exchange contracts	—			—			—			—
	$	(~~682~~357	)	$	(~~3,348~~919	)	$	(1,039	)	$	(4,267	)

Certain of our derivative instruments contain provisions that require compliance with the restrictive covenants of our Senior Secured Credit Facilities. For further information regarding the restrictive covenants of credit facilities, see Note 5 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

If we default under our credit facilities, the lenders could require immediate repayment of the entire outstanding principal balance. If those lenders require immediate repayment, we may not be able to repay them which could result in the foreclosure of substantially all of our assets. In these circumstances, the counterparties to the derivative instruments could request immediate payment or full collateralization on derivative instruments in net liability positions. Certain of our derivative counterparties are also parties to our Senior Secured Credit Facilities.

No collateral has been posted by us in the normal course of business. If the credit-related contingent features underlying these agreements were triggered on ~~March~~June 3130, 2016, we could be required to settle or post the full amount as collateral to the respective agreement counterparties.

We did not have any measurements of financial assets or financial liabilities at fair value on a nonrecurring basis at ~~March~~June 3130, 2016 or December 31, 2015.

NOTE 6. Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows (in thousands):

	AccumulatedForeignCurrencyTranslationAdjustment			~~AccumulatedOtherComprehensiveIncome (Loss)~~AccumulatedDerivativeLoss			AccumulatedOtherComprehensiveLoss
Balances at December 31, 2015	$	(19,734	)	$	~~(19,734~~—	)	$	(19,734	)
Foreign currency translation adjustment, net of tax benefit of $755	4,098			4,098
Foreign currency translation adjustment, net of tax benefit of $1,339	(8,226		)	—			(8,226		)
Balances at March 31, 2016	$	(15,636	)	$	(15,636	)
Net derivative loss, net of taxes of $0	—			(11,293		)	(11,293		)
Balances at June 30, 2016	$	(27,960	)	$	(11,293	)	$	(39,253	)

During the ~~three~~six months ended ~~March~~June 3130, 2016, there were no reclassification adjustments out of accumulated other comprehensive loss to net loss.

NOTE 7. Commitments and Contingencies

Legal Proceedings

Intellectual Property Litigation

As the owner and exclusive licensee of patents, from time to time, we are a party to proceedings challenging these patents, including challenges in U.S. federal courts, foreign courts, foreign patent offices and the U.S. Patent and Trademark Office. Additionally, from time to time, we are a party to litigation we initiate against others we contend infringe these patents, which often results in counterclaims regarding the validity of such patents. At other times, we are party to litigation initiated by others who contend we infringe their patents. It is not possible to reliably predict the outcome of the proceedings described below. However, if we are unable to effectively enforce our intellectual property rights, third parties may become more aggressive in the marketing of competitive products around the world.

In September 2013, LifeNet Health ("LifeNet") filed suit against LifeCell Corporation ("LifeCell") in the U.S. District Court for the Eastern District of Virginia, Norfolk Division. LifeNet alleged that two LifeCell products, Strattice and AlloDerm Ready to Use, infringe LifeNet’s U.S. Patent No. 6,569,200, or the ‘200 Patent. On November 18, 2014, a jury found that the ‘200 Patent was not invalid and was infringed and further awarded LifeNet a lump sum damages amount of $34.7 million. As a result of this decision, we recorded a liability of $34.7 million in the fourth quarter of 2014. We disagree with the result at this stage in the litigation and believe that LifeCell’s defenses to the claims are meritorious. LifeCell will continue to vigorously assert its defenses during the appeal stages of this litigation and intends to defend any further claims by LifeNet. LifeCell has filed an appeal in the U.S. Federal Circuit Court of Appeals in Washington D.C. on multiple grounds. The hearing before the Federal Circuit Court of Appeals was held in March 2016. In September 2015, LifeCell filed suit against LifeNet in the U.S. District Court for the District of New Jersey seeking declaratory judgment that LifeCell’s products do not infringe U.S. Patent No. 9,125,971, or the ‘971 Patent, which was issued to LifeNet the same day. In February 2016, a magistrate judge ordered the case transferred to Virginia, which LifeCell is appealing. LifeCell also filed a petition with United States Patent and Trademark Office to invalidate the ‘971 Patent. The ‘971 Patent is a continuation of the ‘200 Patent.

Products Liability Litigation

LifeCell is a defendant in approximately ~~355~~341 lawsuits filed by individuals alleging personal injury and seeking monetary damages for failed hernia repair procedures using LifeCell’s AlloDerm products. These cases have been consolidated for case management purposes in Middlesex County, New Jersey. The trial court has issued a pre-trial order incorporating the bellwether practice of trying the claims of some plaintiffs to determine the likelihood of settlement or to avoid relitigating common issues in every case. Discovery was completed in four bellwether cases. In August 2015, LifeCell ~~was~~successfullly ~~successful~~obtained ~~in obtaining~~ a summary judgment resulting in the dismissal of two of the four bellwether cases, and the dismissal of the design defect claims in the remaining two bellwether cases. The plaintiffs have appealed these decisions. Trial of the first remaining bellwether case has been postponed and has not yet been rescheduled. Although it is not possible to reliably predict the outcome of the litigation, we believe that our defenses to these claims are meritorious and we will vigorously defend ~~against~~ these ~~suits~~cases ~~vigorously~~. Based on our existing insurance coverage and our defenses to these cases, we do not expect them to have a material impact on our results of operations or our financial position. Because discovery of damages has been limited to the four bellwether cases, we do not know the damages allegedly suffered by the remaining plaintiffs. As such, it is impossible to predict or estimate potential losses if our defenses to these cases are unsuccessful.

LifeCell has been named as a defendant in approximately 258 lawsuits in state and U.S. federal courts alleging personal injury and seeking monetary damages for failed gynecological procedures using a human tissue product processed by LifeCell and sold by one of LifeCell’s distributors, Boston Scientific, under the name Repliform. There are approximately 254 LifeCell cases filed in two consolidated dockets in Middlesex County, Massachusetts. The cases are in the initial phase and no discovery has occurred. Two cases are pending in a multi-district U.S. federal case in West Virginia that is proceeding very slowly. LifeCell has been named, but not served, in 12 cases with multiple plaintiffs and defendants in St. Louis, Missouri State court. The St. Louis cases are aimed at the entire pelvic mesh industry and it is unknown at this time if Repliform was actually implanted in any of the plaintiffs. The two remaining cases are in Delaware and Minnesota. Based on our existing insurance coverage and our defenses to these cases, we do not expect them to have a material impact on our results of operations or our financial position. As these cases are in their early stages it is not possible to predict or estimate potential losses if our defenses to these cases are unsuccessful.19

our defenses to these cases, we do not expect them to have a material impact on our results of operations or our financial position. Because discovery of damages has been limited to the four bellwether cases, we do not know the damages allegedly suffered by the remaining plaintiffs. As such, it is impossible to predict or estimate potential losses if our defenses to these cases are unsuccessful.

LifeCell has been named as a defendant in approximately 270 lawsuits in state and U.S. federal courts alleging personal injury and seeking monetary damages for failed gynecological procedures using a human tissue product processed by LifeCell and sold by one of LifeCell’s distributors, Boston Scientific, under the name Repliform. There are approximately 266 LifeCell cases filed in two consolidated dockets in Middlesex County, Massachusetts. The cases are in the initial phase and no discovery has occurred. Two cases are pending in a multi-district U.S. federal case in West Virginia that is proceeding very slowly. LifeCell has been named, but not served, in 12 cases with multiple plaintiffs and defendants in St. Louis, Missouri State court. The St. Louis cases are aimed at the entire pelvic mesh industry and it is unknown at this time if Repliform was actually implanted in any of the plaintiffs. The two remaining cases are in Delaware and Minnesota. Based on our existing insurance coverage and our defenses to these cases, we do not expect them to have a material impact on our results of operations or our financial position. As these cases are in their early stages it is not possible to predict or estimate potential losses if our defenses to these cases are unsuccessful.

Other Litigation

In 2009, KCI received a subpoena from the U.S. Department of Health and Human Services Office of Inspector General, or OIG, seeking records regarding our billing practices under the local coverage policies of the four regional Durable Medical Equipment Medicare Administrative Contractors, or DME MACs. KCI cooperated with the OIG’s inquiry and provided substantial documentation to the OIG and the U.S. Attorneys’ office in response to its request. The government’s inquiry stemmed from the filing under seal of two 2008 qui tam actions against KCI by two former employees in the U.S. District Court, Central District of California, Western Division. These cases are captioned United States of America, ex rel. Steven J. Hartpence v. Kinetic Concepts, Inc. et al, and United States of America, ex rel. Geraldine Godecke v. Kinetic Concepts, Inc., et al. The complaints ~~contend~~allege that KCI violated the federal False Claims Act by billing in a manner that was not consistent with the Local Coverage Determinations issued by the DME MACs. Plaintiffs ~~and~~ seek recovery of monetary damages. Following the completion of the government’s review and its decision declining to intervene in such suits, the live pleadings were ordered unsealed in 2011. After reviewing the allegations, KCI filed motions seeking the dismissal of the suits on multiple grounds. In 2012, the District Court granted KCI’s motions dismissing all of the claims under the False Claims Act. The cases were appealed to the U.S. Court of Appeals for the Ninth Circuit which reversed the District Court’s dismissal of the suits and remanded the cases back to the District Court for further proceedings. The cases are in their initial phase and the court is considering the objections to it jurisdiction. We believe that our defenses to the claims in the Hartpence and Godecke cases are meritorious and that we have no liability under the False Claims Act for their allegations. However, it is not possible to predict the outcome of this litigation nor is it possible to estimate any damages that may be awarded if we are unsuccessful in the litigation.

We are a party to several additional lawsuits arising in the ordinary course of our business. Additionally, the manufacturing and marketing of medical products necessarily entails an inherent risk of product liability claims. We maintain multiple layers of product liability insurance coverage and we believe these policies and the amounts of coverage are appropriate and adequate.

Other Commitments and Contingencies

As a healthcare supplier, we are subject to extensive government regulation, including laws and regulations directed at ascertaining the appropriateness of reimbursement, preventing fraud and abuse and otherwise regulating reimbursement under various government programs. The marketing, billing, documenting and other practices are all subject to government oversight and review. To ensure compliance with Medicare and other regulations, regional carriers often conduct audits and request patient records and other documents to support claims submitted by us for payment of services rendered to customers.

19 We also are subject to routine pre-payment and post-payment audits of durable medical equipment (“DME”) claims submitted to Medicare. These audits typically involve a complex medical review, by Medicare or its designated contractors and representatives, of documentation supporting the therapy provided by us. While Medicare requires us to obtain a comprehensive physician order prior to providing products and services, we are not required to obtain the written medical record in advance of therapy as long as the underlying medical records reported to us support the coverage criteria and medical necessity information included in such claim. Following a Medicare request for supporting documentation, we are obligated to procure and submit the underlying medical records retained by various clinical providers, medical facilities and prescribers. Obtaining these medical records in connection with a claims audit may be challenging and, in any event, all of these records are subject to further examination, interpretation and dispute by an auditing authority. Under standard Medicare procedures, we are entitled to demonstrate the sufficiency of documentation and the establishment of medical necessity, and we have the right to appeal any adverse determinations. If a determination is made that our records or the patients’ medical records are insufficient to meet medical necessity or Medicare reimbursement requirements for the claims, we could be subject to denial or overpayment demands for claims submitted for

We also are subject to routine pre-payment and post-payment audits of durable medical equipment (“DME”) claims submitted to Medicare. These audits typically involve a complex medical review, by Medicare or its designated contractors and representatives, of documentation supporting the therapy provided by us. While Medicare requires us to obtain a comprehensive physician order prior to providing products and services, we are not required to obtain the written medical record in advance of therapy as long as the underlying medical records reported to us support the coverage criteria and medical necessity information included in such claim. Following a Medicare request for supporting documentation, we are obligated to procure and submit the underlying medical records retained by various clinical providers, medical facilities and prescribers. Obtaining these medical records in connection with a claims audit may be challenging and, in any event, all of these records are subject to further examination, interpretation and dispute by an auditing authority. Under standard Medicare procedures, we are entitled to demonstrate the sufficiency of documentation and the establishment of medical necessity, and we have the right to appeal any adverse determinations. If a determination is made that our records or the patients’ medical records are insufficient to meet medical necessity or Medicare reimbursement requirements for the claims, we could be subject to denial or overpayment demands for claims submitted for Medicare reimbursement. In the rare event that an audit results in major discrepancies of claims records which lacked proof of medical necessity, Medicare may be entitled to take additional corrective measures, including: extrapolation of the results of the audit across a wider population of claims, submitting recoupment demands for claims other than those examined in the audit, or placing the organization on a full prepayment review. Over the twelve month period ended March 31, 2016, these audits have averaged approximately 12% of our claims. While eventually receiving payment on a high percent of the claims subject to these audits, payment timeliness may range from a few months up to a year resulting in increasing Medicare accounts receivable balances.

On June 30, 2014, KCI entered into a settlement agreement with Wake Forest University Health Sciences to fully and finally resolve the historical patent and royalty disputes between them relating to negative pressure wound therapy. As of March 31, 2016, the accompanying consolidated balance sheet included $83.8 million under the caption “accrued expenses and other” and $28.0 million under the caption “other non-current liabilities” representing the net present value of remaining payments under the settlement agreement discounted using our incremental borrowing rate as the discount rate.

Medicare reimbursement. In the rare event that an audit results in major discrepancies of claims records which lacked proof of medical necessity, Medicare may be entitled to take additional corrective measures, including: extrapolation of the results of the audit across a wider population of claims, submitting recoupment demands for claims other than those examined in the audit, or placing the organization on a full prepayment review. Over the twelve month period ended June 30, 2016, these audits have averaged approximately 12% of our claims. While eventually receiving payment on a high percent of the claims subject to these audits, payment timeliness may range from a few months up to a year resulting in increasing Medicare accounts receivable balances.

On June 30, 2014, KCI entered into a settlement agreement with Wake Forest University Health Sciences to fully and finally resolve the historical patent and royalty disputes between them relating to negative pressure wound therapy. As of June 30, 2016, the accompanying consolidated balance sheet included $28.4 million under the caption “accrued expenses and other" representing the net present value of remaining payments under the settlement agreement discounted using our incremental borrowing rate as the discount rate.

NOTE 8. Segment Information

The Company is engaged in the rental and sale of advanced wound therapeutics and regenerative medicine products in approximately 80 countries worldwide through direct sales and indirect operations. We have two reportable operating segments which correspond to our two businesses: Advanced Wound Therapeutics ("AWT") and Regenerative Medicine. Our AWT business is conducted by KCI and its subsidiaries, including Systagenix, while our Regenerative Medicine business is conducted by LifeCell and its subsidiaries. In most countries where we operate, certain aspects of our two businesses are supported by the same administrative staff, systems and infrastructure and, as such, we have allocated these costs between the businesses based on allocation methods including headcount, revenue and other methods as deemed appropriate. We measure segment profit (loss) as operating earnings (loss), which is defined as income (loss) before interest and other income, interest expense, foreign currency gains and losses, derivative instruments gains and losses and income taxes. All intercompany transactions are eliminated in computing revenue and operating earnings (loss).

Information on segments and a reconciliation of consolidated totals are as follows (in thousands):

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
Revenue:
Advanced Wound Therapeutics	$	~~339~~354,~~042~~968		$	~~337~~354,~~259~~214		$	694,010		$	691,473
Regenerative Medicine	~~109~~114,~~874~~905			~~104~~103,~~169~~529			224,779			207,698
Other operations (1)	2,~~450~~548			23,~~622~~902			4,998			6,524
Total revenue	$	~~451~~472,~~366~~421		$	~~444~~461,~~050~~645		$	923,787		$	905,695
Operating earnings:
Advanced Wound Therapeutics	$	99107,~~664~~633		$	~~112~~117,~~885~~642		$	207,297		$	230,527
Regenerative Medicine	3942,~~275~~523			3435,~~019~~346			81,798			69,365
Other operations (1)	~~551~~465			~~447~~542			1,016			989
Non-allocated costs:
General headquarter expense (2)	(1,~~568~~160		)	(1,~~423~~526		)	(2,728		)	(2,949		)
Equity-based compensation	(~~768~~834		)	(~~535~~770		)	(1,602		)	(1,305		)
Business optimization and transaction-related expenses (3)	(1727,~~685~~028		)	(1516,~~376~~352		)	(44,713		)	(31,728		)
Acquired intangible asset amortization (4)	(4241,~~201~~160		)	(4544,~~877~~712		)	(83,361		)	(90,589		)
Total non-allocated costs	(6270,~~222~~182		)	(63,~~211~~360		)	(132,404		)	(126,571		)
Total operating earnings	$	7780,~~268~~439		$	8490,~~140~~170		$	157,707		$	174,310


(1)	Represents contract manufacturing operations conducted at our manufacturing facility in Gargrave, England.

(2) Represents general headquarter expenses not allocated to the individual segments~~, including depreciation associated with our purchase accounting fixed asset step up to fair value~~.


(3)	Represents restructuring-related expenses associated with our business optimization initiatives as well as management fees and costs associated with acquisition, disposition and financing activities.


(4)	Represents amortization of acquired intangible assets related to our 2011 LBO, our acquisition of Systagenix in October 2013 and other technology acquisitions.

2122

NOTE 9. Guarantor Condensed Consolidating Financial Statements

Our First Lien Notes and Existing Notes are fully and unconditionally guaranteed, jointly and severally, by us and each of our material 100% owned subsidiaries, other than the subsidiaries that are co-issuers of the notes, foreign subsidiaries and subsidiaries whose only assets are investments in foreign subsidiaries. The non-guarantor subsidiaries do not have any payment obligations under the First Lien Notes or Existing Notes. Subject to the terms of the First Lien Notes and Existing Notes indentures, the guarantee of a subsidiary guarantor will terminate upon:


(1)	a sale or other disposition (including by way of consolidation or merger) of the capital stock of such guarantor or the sale or disposition of all or substantially all the assets of such subsidiary guarantor (other than to the Company or a restricted subsidiary) otherwise permitted by the First Lien Notes or Existing Notes indentures,


(2)	the designation in accordance with the First Lien Notes or Existing Notes indenture of the guarantor as an unrestricted subsidiary or the occurrence of any event after which the guarantor is no longer a restricted subsidiary,


(3)	defeasance or discharge of the First Lien Notes or Existing Notes, or


(4)	the achievement of investment grade status by the First Lien Notes or Existing Notes; provided that such guarantee shall be reinstated upon the reversion date.

In the event of a bankruptcy, liquidation or reorganization of any non-guarantor subsidiary, such non-guarantor subsidiary will pay the holders of its debt and other liabilities, including its trade creditors, before it will be able to distribute any of its assets to us. In the future, any non-U.S. subsidiaries, immaterial subsidiaries and subsidiaries that we designate as unrestricted subsidiaries under the First Lien Notes and Existing Notes indentures will not guarantee the First Lien Notes or Existing Notes. As of ~~March~~June 3130, 2016, there were no restrictions on the ability of subsidiary guarantors to transfer funds to the parent company.

As a result of the guarantee arrangements, we are presenting the following condensed consolidated balance sheets, statements of operations and comprehensive income (loss), and statements of cash flows of the issuer, the guarantor subsidiaries and the non-guarantor subsidiaries.

2223

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Balance Sheet

~~March~~June 3130, 2016

(in thousands)

(unaudited)

	Acelity L.P. Inc. Parent Company		Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Consolidated
Assets:
Current assets:
Cash and cash equivalents	$	398	$	6625,~~900~~029		$	71,~~458~~895	$	~~148~~71,~~860~~875	$	—		$	~~223~~99,~~616~~197
Accounts receivable, net	—		~~199~~206,~~611~~624			6159,~~760~~412		~~158~~147,~~512~~404		—			~~419~~413,~~883~~440
Inventories, net	—		88100,~~390~~069			~~115~~113,~~886~~756		~~112~~117,~~654~~663		(~~128~~133,~~130~~905		)	~~188~~197,~~800~~583
Deferred income taxes	—		4934,~~794~~892			820,~~286~~470		—		(143,~~299~~394		)	4351,~~781~~968
Prepaid expenses and other	—		1222,~~504~~001			3,~~771~~746		~~244~~243,~~835~~526		(~~231~~229,~~246~~156		)	2940,~~864~~117
Intercompany receivables	166		2,~~128~~165,~~300~~186			23,~~871~~131,~~122~~862		7156,~~087~~689		(5,~~070~~353,~~675~~903		)	—
Total current assets	564		2,~~545~~553,~~499~~801			3,~~068~~331,~~283~~141		~~735~~637,~~948~~157		(5,~~444~~720,~~350~~358		)	~~905~~802,~~944~~305
Net property, plant and equipment	—		~~297~~299,~~632~~623			5955,~~575~~431		~~119~~113,~~019~~096		(~~210~~207,~~218~~581		)	~~266~~260,~~008~~569
Deferred income taxes	—		—			—		2422,~~262~~333		—			2422,~~262~~333
Goodwill	—		2,511,417			732,138		162,920		—			3,406,475
Identifiable intangible assets, net	—		~~239~~227,~~052~~982			1,~~686~~669,~~938~~038		~~252~~242,~~874~~346		—			2,~~178~~139,~~864~~366
Other non-current assets	—		1,~~115~~598			282		3,~~250~~153		—			45,~~647~~033
Intercompany loan receivables	—		~~735~~730,000			~~439~~443,~~937~~480		—		(1,~~174~~173,~~937~~480		)	—
Intercompany investments	~~592~~549,~~430~~533		~~428~~463,~~232~~886			—		—		(1,~~020~~013,~~662~~419		)	—
	$	~~592~~550,~~994~~097	$	6,~~757~~788,~~947~~307		$	56,~~987~~231,~~153~~510	$	1,~~298~~181,~~273~~005	$	(78,~~850~~114,~~167~~838	)	$	6,~~786~~636,~~200~~081
Liabilities and Equity:
Current liabilities:
Accounts payable	$	—	$	1514,~~452~~957		$	13,~~680~~619	$	2324,~~534~~142	$	—		$	52,~~666~~718
Accrued expenses and other	—		~~287~~188,~~448~~290			~~253~~255,~~676~~801		6667,~~391~~856		(~~187~~185,~~311~~645		)	~~420~~326,~~204~~302
Intercompany payables	10,~~332~~340		12,~~801~~016,~~863~~381			2,~~745~~819,~~691~~472		~~512~~507,~~789~~710		(5,~~070~~353,~~675~~903		)	—
Current installments of long-term debt	—		2223,~~258~~307			—		—		—			2223,~~258~~307
Income taxes payable	—		—			51,~~159~~357		43,~~284~~175		(~~606~~160		)	84,~~837~~372
Deferred income taxes	—		—			113,595		143,~~299~~394		(143,~~299~~394		)	113,595
Total current liabilities	10,~~332~~340		2,~~127~~242,~~021~~935			3,~~131~~203,~~801~~844		~~621~~606,~~297~~277		(5,~~272~~543,~~891~~102		)	~~617~~520,~~560~~294
Long-term debt, net of current installments, discount and debt issuance costs	—		4,820,113			—		—		—			4,820,113
Long-term debt, net of current installments, premium, discount and debt issuance costs	—		4,845,783			—		—		—			4,845,783
Non-current tax liabilities	—		15,~~259~~609			15,~~287~~640		3,~~148~~284		—			3334,~~694~~533
Deferred income taxes	—		5537,~~359~~762			~~603~~605,~~250~~486		3938,~~862~~344		—			~~698~~681,~~471~~592
Other non-current liabilities	~~909~~1,031		288,~~451~~834			2,~~459~~524		2,~~790~~764		—			3415,~~609~~153
Intercompany loan payables	—		~~435~~438,~~607~~670			~~735~~730,000		4,~~330~~810		(1,~~174~~173,~~937~~480		)	—
Intercompany advance	—		—			1134,~~241~~643		—		(1134,~~241~~643		)	—
Total liabilities	11,~~241~~371		7,~~481~~589,~~810~~593			4,~~489~~692,~~038~~137		~~671~~655,~~427~~479		(6,~~449~~851,~~069~~225		)	6,~~204~~097,~~447~~355
Total equity	~~581~~538,~~753~~726		(~~723~~801,~~863~~286		)	1,~~498~~539,~~115~~373		~~626~~525,~~846~~526		(1,~~401~~263,~~098~~613		)	~~581~~538,~~753~~726
	$	~~592~~550,~~994~~097	$	6,~~757~~788,~~947~~307		$	56,~~987~~231,~~153~~510	$	1,~~298~~181,~~273~~005	$	(78,~~850~~114,~~167~~838	)	$	6,~~786~~636,~~200~~081

2324

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Balance Sheet

December 31, 2015

(in thousands)

	Acelity L.P. Inc. Parent Company		Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Eliminations			Consolidated
Assets:
Current assets:
Cash and cash equivalents	$	398	$	12,859		$	4,919	$	70,233	$	—		$	88,409
Accounts receivable, net	—		202,377			58,080		153,074		—			413,531
Inventories, net	—		89,929			87,519		104,904		(101,043		)	181,309
Deferred income taxes	—		66,235			8,286		—		—			74,521
Prepaid expenses and other	—		15,199			7,519		244,833		(232,566		)	34,985
Intercompany receivables	166		2,098,061			2,828,639		16,279		(4,943,145		)	—
Total current assets	564		2,484,660			2,994,962		589,323		(5,276,754		)	792,755
Net property, plant and equipment	—		294,855			59,833		127,858		(209,470		)	273,076
Deferred income taxes	—		—			—		29,909		—			29,909
Goodwill	—		2,510,765			732,138		162,920		—			3,405,823
Identifiable intangible assets, net	—		250,635			1,704,521		263,932		—			2,219,088
Other non-current assets	—		1,029			282		4,793		—			6,104
Intercompany loan receivables	—		740,000			436,432		—		(1,176,432		)	—
Intercompany investments	613,540		353,768			—		—		(967,308		)	—
	$	614,104	$	6,635,712		$	5,928,168	$	1,178,735	$	(7,629,964	)	$	6,726,755
Liabilities and Equity:
Current liabilities:
Accounts payable	$	—	$	18,013		$	14,129	$	25,768	$	—		$	57,910
Accrued expenses and other	—		234,036			260,404		68,207		(189,207		)	373,440
Intercompany payables	10,115		1,730,435			2,689,502		513,093		(4,943,145		)	—
Current installments of long-term debt	—		22,130			—		—		—			22,130
Income taxes payable	—		—			—		3,561		—			3,561
Deferred income taxes	—		—			113,595		—		—			113,595
Total current liabilities	10,115		2,004,614			3,077,630		610,629		(5,132,352		)	570,636
Long-term debt, net of current installments, discount and debt issuance costs	—		4,720,363			—		—		—			4,720,363
Long-term debt, net of current installments, premium, discount and debt issuance costs	—		4,720,363			—		—		—			4,720,363
Non-current tax liabilities	—		15,046			14,965		4,822		—			34,833
Deferred income taxes	—		110,076			609,281		41,380		—			760,737
Other non-current liabilities	824		29,079			4,472		2,646		—			37,021
Intercompany loan payables	—		432,545			740,000		3,887		(1,176,432		)	—
Intercompany advance	—		—			70,045		—		(70,045		)	—
Total liabilities	10,939		7,311,723			4,516,393		663,364		(6,378,829		)	6,123,590
Total equity	603,165		(676,011		)	1,411,775		515,371		(1,251,135		)	603,165
	$	614,104	$	6,635,712		$	5,928,168	$	1,178,735	$	(7,629,964	)	$	6,726,755

2425

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)

	For the three months ended March 31, 2016
	For the three months ended June 30, 2016
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	~~150~~155,~~420~~345		$	—		$	1920,~~679~~077		$	—		$	~~170~~175,~~099~~422
Sales	—			9099,~~781~~880			~~245~~251,~~943~~328			~~251~~215,~~262~~941			(~~306~~270,~~719~~150		)	~~281~~296,~~267~~999
Total revenue	—			~~241~~255,~~201~~225			~~245~~251,~~943~~328			~~270~~236,~~941~~018			(~~306~~270,~~719~~150		)	~~451~~472,~~366~~421
Rental expenses	2025			81,~~488~~183			~~176~~866			35,~~951~~427			(4241,~~740~~707		)	7475,~~895~~794
Cost of sales	—16			9994,~~612~~791			~~160~~161,~~795~~862			9290,~~681~~578			(~~274~~269,~~509~~129		)	78,~~579~~118
Gross profit (loss)	(2041		)	6079,~~101~~251			8488,~~972~~600			~~142~~110,~~309~~013			1040,~~530~~686			~~297~~318,~~892~~509
Selling, general and administrative expenses	~~748~~793			8096,~~974~~350			4241,~~374~~786			4043,~~733~~526			(~~385~~261		)	~~164~~182,~~444~~194
Research and development expenses	—			5,~~764~~469			5,~~019~~194			34,~~195~~054			—			1314,~~978~~717
Acquired intangible asset amortization	—			11,~~584~~074			19,~~364~~242			1110,~~254~~843			—			4241,~~202~~159
Operating earnings (loss)	(~~768~~834		)	(3833,~~221~~642		)	1822,~~215~~378			8751,~~127~~590			1040,~~915~~947			7780,~~268~~439
Non-operating intercompany transactions	—			(131,~~402~~226		)	6163,~~713~~824			(5195,~~352~~051		)	411			—
Interest income and other	—			16,~~508~~402			73,~~617~~112			71511			(2419,~~089~~436		)	~~107~~589
Interest expense	—			(~~116~~113,~~088~~372		)	(16,~~537~~430		)	(1662		)	2419,~~089~~436			(~~108~~110,~~552~~428		)
Loss on extinguishment of debt	—			(310,~~609~~107		)	—			—			—			(310,~~609~~107		)
Foreign currency gain (loss)	—			~~(13~~7,~~044~~159		)	~~737~~853			~~7,977~~986			—			(48,~~330~~998		)
Derivative instruments loss	—			(~~682~~357		)	—			—			—			(~~682~~357		)
Earnings (loss) before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(~~768~~834		)	(~~156~~102,~~538~~691		)	16173,~~745~~737			89(142,~~807~~026		)	1040,~~956~~948			(3930,~~798~~866		)
Income tax expense (benefit)	—			(331,~~980~~171		)	(~~846~~956		)	21(8,~~003~~624		)	—			(1310,~~823~~751		)
Earnings (loss) before equity in earnings (loss) of subsidiaries	(~~768~~834		)	(~~122~~101,~~558~~520		)	17174,~~591~~693			68(133,~~804~~402		)	1040,~~956~~948			(2520,~~975~~115		)
Equity in earnings (loss) of subsidiaries	(2519,~~207~~281		)	7435,~~464~~654			68(133,~~804~~402		)	—			~~(118~~117,~~061~~029		)	—
Net earnings (loss)	$	(2520,~~975~~115	)	$	(4865,~~094~~866	)	$	8641,~~395~~291		$	68(133,~~804~~402	)	$	~~(107~~157,~~105~~977	)	$	(2520,~~975~~115	)
Total comprehensive income (loss)	$	(2143,~~877~~732	)	$	(4389,~~996~~483	)	$	9017,~~493~~674		$	72(157,~~902~~019	)	$	~~(119~~228,~~399~~828	)	$	(2143,~~877~~732	)

2526

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)

	For the three months ended March 31, 2015
	For the three months ended June 30, 2015
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	~~149~~157,~~698~~674		$	—		$	2322,~~141~~723		$	—		$	~~172~~180,~~839~~397
Sales	—			8387,~~737~~967			~~239~~217,~~691~~740			~~229~~203,~~663~~091			(~~281~~227,~~880~~550		)	~~271~~281,~~211~~248
Total revenue	—			~~233~~245,~~435~~641			~~239~~217,~~691~~740			~~252~~225,~~804~~814			(~~281~~227,~~880~~550		)	~~444~~461,~~050~~645
Rental expenses	2115			7577,~~873~~207			32,~~467~~673			4140,~~365~~860			(42,~~548~~886		)	7877,~~178~~869
Cost of sales	4310			8990,~~496~~719			~~159~~136,~~253~~937			8785,~~974~~024			(~~263~~237,~~352~~181		)	7375,~~414~~509
Gross profit (loss)	(6425		)	6877,~~066~~715			7678,~~971~~130			~~123~~99,~~465~~930			2452,~~020~~517			~~292~~308,~~458~~267
Selling, general and administrative expenses	~~471~~745			6874,~~519~~827			3640,~~716~~324			4243,~~308~~203			(~~251~~105		)	~~147~~158,~~763~~994
Research and development expenses	—			5,~~617~~245			45,~~896~~643			43,~~165~~503			—			14,~~678~~391
Acquired intangible asset amortization	—			13,~~880~~304			19,~~456~~313			12,~~541~~095			—			4544,~~877~~712
Operating earnings (loss)	(~~535~~770		)	(1915,~~950~~661		)	1512,~~903~~850			6441,~~451~~129			2452,~~271~~622			8490,~~140~~170
Non-operating intercompany transactions	—			(122,~~682~~536		)	30188,~~849~~971			(29211,~~190~~627		)	23120			—
Interest income and other	—			16,~~762~~799			36,~~063~~335			~~103~~52			(1923,~~781~~119		)	~~147~~67
Interest expense	—			(~~107~~113,~~782~~673		)	(16,~~718~~798		)	(722		)	1923,~~781~~119			(~~104~~107,~~726~~374		)
Foreign currency gain (loss)	—			35(10,~~006~~211		)	~~(1,593~~695		)	~~(14~~2,~~013~~717		)	—			19(6,~~400~~799		)
Derivative instruments loss	—			(~~3,348~~919		)	—			—			—			(~~3,348~~919		)
Earnings (loss) before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(~~535~~770		)	(80101,~~994~~129		)	31192,~~504~~053			21(167,~~344~~751		)	2452,~~294~~742			(424,~~387~~855		)
Income tax expense (benefit)	—			~~415~~(9,452		)	~~141~~(1,306		)	~~(412~~3,534		)	—			~~144~~(7,224		)
Earnings (loss) before equity in earnings (loss) of subsidiaries	(~~535~~770		)	(8191,~~409~~677		)	31193,~~363~~359			21(171,~~756~~285		)	2452,~~294~~742			(417,~~531~~631		)
Equity in earnings (loss) of subsidiaries	(316,~~996~~861		)	4819,~~953~~724			21(171,~~756~~285		)	—			~~(66~~168,~~713~~422		)	—
Net earnings (loss)	$	(417,~~531~~631	)	$	(3271,~~456~~953	)	$	5322,~~119~~074		$	21(171,~~756~~285	)	$	~~(42~~221,~~419~~164	)	$	(417,~~531~~631	)
Total comprehensive income (loss)	$	(1112,~~602~~696	)	$	(3967,~~527~~018	)	$	4627,~~048~~009		$	14(166,~~685~~350	)	$	~~(21,~~206,359	)	$	(1112,~~602~~696	)

2627

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)



	For the six months ended June 30, 2016
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	305,765		$	—		$	39,756		$	—		$	345,521
Sales	—			190,661			497,271			467,203			(576,869		)	578,266
Total revenue	—			496,426			497,271			506,959			(576,869		)	923,787
Rental expenses	45			162,671			1,042			71,378			(84,447		)	150,689
Cost of sales	16			194,403			322,657			183,259			(543,638		)	156,697
Gross profit (loss)	(61		)	139,352			173,572			252,322			51,216			616,401
Selling, general and administrative expenses	1,541			177,324			84,160			84,259			(646		)	346,638
Research and development expenses	—			11,233			10,213			7,249			—			28,695
Acquired intangible asset amortization	—			22,658			38,606			22,097			—			83,361
Operating earnings (loss)	(1,602		)	(71,863		)	40,593			138,717			51,862			157,707
Non-operating intercompany transactions	—			29,824			170,537			(200,403		)	42			—
Interest income and other	—			32,910			10,729			582			(43,525		)	696
Interest expense	—			(229,460		)	(32,967		)	(78		)	43,525			(218,980		)
Loss on extinguishment of debt	—			(13,716		)	—			—			—			(13,716		)
Foreign currency gain (loss)	—			(5,885		)	1,590			8,963			—			4,668
Derivative instruments loss	—			(1,039		)	—			—			—			(1,039		)
Earnings (loss) before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(1,602		)	(259,229		)	190,482			(52,219		)	51,904			(70,664		)
Income tax expense (benefit)	—			(35,151		)	(1,802		)	12,379			—			(24,574		)
Earnings (loss) before equity in earnings (loss) of subsidiaries	(1,602		)	(224,078		)	192,284			(64,598		)	51,904			(46,090		)
Equity in earnings (loss) of subsidiaries	(44,488		)	110,118			(64,598		)	—			(1,032		)	—
Net earnings (loss)	$	(46,090	)	$	(113,960	)	$	127,686		$	(64,598	)	$	50,872		$	(46,090	)
Total comprehensive income (loss)	$	(65,609	)	$	(133,479	)	$	108,167		$	(84,117	)	$	109,429		$	(65,609	)

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Operations and Comprehensive Income (Loss)

(in thousands)

(unaudited)



	For the six months ended June 30, 2015
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Revenue:
Rental	$	—		$	307,372		$	—		$	45,864		$	—		$	353,236
Sales	—			171,704			457,431			432,754			(509,430		)	552,459
Total revenue	—			479,076			457,431			478,618			(509,430		)	905,695
Rental expenses	36			153,080			6,140			82,225			(85,434		)	156,047
Cost of sales	53			180,215			296,190			172,998			(500,533		)	148,923
Gross profit (loss)	(89		)	145,781			155,101			223,395			76,537			600,725
Selling, general and administrative expenses	1,216			143,346			77,040			85,511			(356		)	306,757
Research and development expenses	—			10,862			10,539			7,668			—			29,069
Acquired intangible asset amortization	—			27,184			38,769			24,636			—			90,589
Operating earnings (loss)	(1,305		)	(35,611		)	28,753			105,580			76,893			174,310
Non-operating intercompany transactions	—			20,854			219,820			(240,817		)	143			—
Interest income and other	—			33,561			9,398			155			(42,900		)	214
Interest expense	—			(221,455		)	(33,516		)	(29		)	42,900			(212,100		)
Foreign currency gain (loss)	—			24,795			(898		)	(11,296		)	—			12,601
Derivative instruments loss	—			(4,267		)	—			—			—			(4,267		)
Earnings (loss) before income taxes (benefit) and equity in earnings (loss) of subsidiaries	(1,305		)	(182,123		)	223,557			(146,407		)	77,036			(29,242		)
Income tax expense (benefit)	—			(9,037		)	(1,165		)	3,122			—			(7,080		)
Earnings (loss) before equity in earnings (loss) of subsidiaries	(1,305		)	(173,086		)	224,722			(149,529		)	77,036			(22,162		)
Equity in earnings (loss) of subsidiaries	(20,857		)	68,677			(149,529		)	—			101,709			—
Net earnings (loss)	$	(22,162	)	$	(104,409	)	$	75,193		$	(149,529	)	$	178,745		$	(22,162	)
Total comprehensive income (loss)	$	(24,298	)	$	(106,545	)	$	73,057		$	(151,665	)	$	185,153		$	(24,298	)

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Cash Flows

(in thousands)

(unaudited)

	For the three months ended March 31, 2016
	For the six months ended June 30, 2016
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash flows from operating activities:
Net earnings (loss)	$	(2546,~~975~~090	)	$	(48113,~~094~~960	)	$	86127,~~395~~686		$	68(64,~~804~~598	)	$	~~(107~~50,~~105~~872	)	$	(2546,~~975~~090	)
Adjustments to reconcile net earnings (loss) to net cash provided (used) by operating activities	~~985~~1,829			~~144~~228,~~348~~754			(~~389~~170,653		)	~~(23~~1,~~268~~232		)	(1754,~~516~~651		)	~~104~~6,~~160~~511
Net cash provided (used) by operating activities	(2444,~~990~~261		)	96114,~~254~~794			86(42,~~006~~967		)	45(63,~~536~~366		)	(~~124~~3,~~621~~779		)	78(39,~~185~~579		)
Cash flows from investing activities:
Net additions to property, plant and equipment	—			(4996,~~827~~612		)	(3,~~842~~415		)	(1021,~~099~~447		)	4585,~~320~~616			(1835,~~448~~858		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			(88574		)	(24,~~260~~104		)	~~1,219~~994			—			(13,~~129~~684		)
Net cash provided (used) by investing activities	—			(4997,~~915~~186		)	(67,~~102~~519		)	(820,~~880~~453		)	4585,~~320~~616			(1939,~~577~~542		)
Cash flows from financing activities:
Settlement of profits interest units	(217		)	—			—			—			—			(217		)
Settlement of equity-based awards	(226		)	—			—			—			—			(226		)
Proceeds from first lien senior secured notes	—			400,000			—			—			—			400,000
Proceeds from revolving credit facility	—			25,000			—			—			—			25,000
Repayments of long-term debt and capital lease obligations	—			(317,731		)	—			—			—			(317,731		)
Proceeds from debt issuance	—			595,044			—			—			—			595,044
Debt issuance costs	—			(8,407		)	—			—			—			(8,407		)
Repayments of long-term debt and capital lease obligations	—			(518,568		)	—			(2		)	—			(518,570		)
Proceeds (payments) on intercompany loans	—			8,062			(8,505		)	443			—			—
Debt issuance costs	—			(12,899		)	—			—			—			(12,899		)
Proceeds (payments) on intercompany investments	25,207			(74,222		)	(68,860		)	38,574			79,301			—
Proceeds (payments) on intercompany loans	—			16,125			(17,048		)	923			—			—
Net cash provided (used) by financing activities	24,990			7,702			(77,365		)	39,017			79,301			73,645
Proceeds (payments) on intercompany investments	44,487			(110,140		)	64,510			82,980			(81,837		)	—
Effect of exchange rate changes on cash and cash equivalents	—			—			—			2,954			—			2,954
Net cash provided (used) by financing activities	44,261			(5,438		)	47,462			83,901			(81,837		)	88,349
Net increase (decrease) in cash and cash equivalents	—			54,041			2,539			78,627			—			135,207
Effect of exchange rate changes on cash and cash equivalents	—			—			—			1,560			—			1,560
Net increase (decrease) in cash and cash equivalents	—			12,170			(3,024		)	1,642			—			10,788
Cash and cash equivalents, beginning of period	398			12,859			4,919			70,233			—			88,409
Cash and cash equivalents, end of period	$	398		$	6625,~~900~~029		$	71,~~458~~895		$	~~148~~71,~~860~~875		$	—		$	~~223~~99,~~616~~197

2730

Condensed Consolidating Parent Company, Co-Issuers,

Guarantor and Non-Guarantor Statement of Cash Flows

(in thousands)

(unaudited)

	For the three months ended March 31, 2015
	For the six months ended June 30, 2015
	Acelity L.P. Inc. Parent Company			Kinetic Concepts, Inc. and KCI USA, Inc. Borrower			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Eliminations			Consolidated
Cash flows from operating activities:
Net earnings (loss)	$	(422,~~531~~162	)	$	(32104,~~456~~409	)	$	5375,~~119~~193		$	21(149,~~756~~529	)	$	~~(42~~178,~~419~~745	)	$	(422,~~531~~162	)
Adjustments to reconcile net loss to net cash provided (used) by operating activities	12,~~107~~708			48159,~~156~~336			52(126,~~609~~725		)	1542,~~657~~979			(1060,~~047~~140		)	~~107~~18,~~482~~158
Net cash provided (used) by operating activities	(319,~~424~~454		)	1554,~~700~~927			~~105~~(51,~~728~~532		)	37(106,~~413~~550		)	~~(52~~118,~~466~~605		)	~~102~~(4,~~951~~004		)
Cash flows from investing activities:
Net additions to property, plant and equipment	—			(2672,~~027~~883		)	(24,~~356~~094		)	(111,~~082~~729		)	1554,~~618~~988			(1333,~~847~~718		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			(130		)	(1,820		)	129			—			(1,821		)
Businesses acquired in purchase transactions, net of cash acquired	—			—			—			(2,948		)	—			(2,948		)
Net cash provided (used) by investing activities	—			(26,157		)	(4,176		)	(953		)	15,618			(15,668		)
Decrease (increase) in identifiable intangible assets and other non-current assets	—			9			(3,595		)	(60		)	—			(3,646		)
Net cash provided (used) by investing activities	—			(72,874		)	(7,689		)	(14,737		)	54,988			(40,312		)
Cash flows from financing activities:
Distribution to limited partners	(55		)	—			—			—			—			(55		)
Settlement of profits interest units	(517		)	—			—			—			—			(517		)
Settlement of equity-based awards	(1,348		)	—			—			—			—			(1,348		)
Repayments of long-term debt and capital lease obligations	—			(6,446		)	—			31			—			(6,415		)
Proceeds from revolving credit facility	—			30,000			—			—			—			30,000
Payment of debt issuance costs	—			(6,256		)	—			—			—			(6,256		)
Repayments of long-term debt and capital lease obligations	—			(12,916		)	(2,500		)	27			—			(15,389		)
Proceeds (payments) on intercompany loans	—			8,063			(6,770		)	(1,293		)	—			—
Debt issuance costs	—			(6,256		)	—			—			—			(6,256		)
Proceeds (payments) on intercompany investments	3,996			24,124			(96,281		)	31,313			36,848			—
Proceeds (payments) on intercompany loans	—			16,125			(11,399		)	(4,726		)	—			—
Net cash provided (used) by financing activities	3,424			19,485			(103,051		)	30,051			36,848			(13,243		)
Proceeds (payments) on intercompany investments	20,857			5,830			71,621			75,285			(173,593		)	—
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(7,072		)	—			(7,072		)
Net cash provided (used) by financing activities	19,454			32,783			57,722			70,586			(173,593		)	6,952
Net increase (decrease) in cash and cash equivalents	—			9,028			(1,499		)	59,439			—			66,968
Effect of exchange rate changes on cash and cash equivalents	—			—			—			(5,025		)	—			(5,025		)
Net increase (decrease) in cash and cash equivalents	—			14,836			(1,499		)	(55,726		)	—			(42,389		)
Cash and cash equivalents, beginning of period	398			41,027			1,499			140,617			—			183,541
Cash and cash equivalents, end of period	$	398		$	5055,~~055~~863		$	—		$	~~200~~84,~~056~~891		$	—		$	~~250~~141,~~509~~152

2831

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with the condensed consolidated financial statements and accompanying notes included in this report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in our “Risk Factors” (Part II, Item 1A.), including those previously disseminated in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

OVERVIEW

We are a leading global medical technology company committed to the development and commercialization of advanced wound care and regenerative medicine solutions. We were formed by uniting the strengths of three organizations, KCI, Systagenix and LifeCell, into our two business segments: Advanced Wound Therapeutics ("AWT") and Regenerative Medicine. Our mission is to change the clinical practice of medicine with solutions that speed healing, reduce complications, create economic value and improve patients’ lives. We offer a broad range of products that can be used across clinical applications, care settings and clinician groups to accelerate soft tissue healing, improve clinical outcomes and reduce overall costs of care. Our product offerings are backed by an extensive body of scientific, clinical and economic outcomes, data that demonstrate the clinical efficacy and value proposition of our products. By offering a range of complementary solutions that are often used together or in sequence across multiple care settings, we are able to address patients’ needs throughout the healing process and offer healthcare providers a single source for addressing such needs.

Our AWT business is focused on the development and commercialization of advanced devices and advanced wound dressings. Our advanced devices business is primarily engaged in marketing several technology platforms, including NPWT, surgical and incision management and epidermal grafting. For patients suffering from traumatic, surgical or chronic wounds, such as diabetic foot ulcers, our NPWT devices facilitate accelerated healing that was unattainable prior to the introduction of NPWT. Our advanced wound dressings business markets wound dressing technologies for the purpose of managing chronic and acute wounds. Our advanced wound dressings are designed to maintain a moist wound environment, while managing exudate, to promote healing and to protect the wound site from infection. Our AWT business is primarily conducted by KCI and its operating subsidiaries, including Systagenix.

Our Regenerative Medicine business is primarily focused on the development and commercialization of regenerative and reconstructive acellular tissue matrices for use in general and reconstructive surgical procedures to reinforce soft tissue defects. We offer tissue matrices for a variety of reconstructive procedures, including post-mastectomy breast reconstruction and the reinforcement of abdominal wall defects. Our tissue matrices are engineered to encourage rapid tissue incorporation, reducing morbidity for patients, while providing optimal reconstructive outcomes. In addition to our acellular tissue matrices, our Regenerative Medicine business markets complementary autologous fat grafting solutions for reconstructive and aesthetic applications. Our Regenerative Medicine business is primarily conducted by LifeCell and its operating subsidiaries.

We are a global company with approximately 24%, of our revenues generated outside the United States for both the ~~three~~second ~~months~~quarter ~~ended~~and ~~March~~first ~~31,~~six months of 2016, and our products are available in approximately 80 countries. We have invested in direct sales and marketing channels and distributors in order to expand our presence in these markets to meet the needs of our customers and payers across clinical applications, care settings and clinician groups. A critical component of marketing our portfolio of solutions and services is our sales organization of approximately 1,~~800~~700 professionals working across multiple care settings and specialties. This sales infrastructure enables us to market our products directly with trained medical professionals in specific care settings in the United States, Canada, Western Europe and key emerging markets. We also have established strong relationships globally with key constituencies, including hospitals, post-acute facilities, group purchasing organizations, or GPOs, payers and other key clinical and economic decision makers by offering comprehensive customer service and clinical education.

We have two reportable operating segments which correspond to our two businesses: AWT and Regenerative Medicine. We also have other revenue which consists of contract manufacturing operations performed at our manufacturing facility in Gargrave, England.

2932

Strategic Transformation

Since our 2011 LBO, we have transformed our business strategically, operationally and financially. This transformation resulted from the re-alignment of our product portfolio through acquisitions and divestitures, expansion into developed and emerging markets, increased commitment to product innovation and new product launches and cost saving initiatives. Our transformation culminated in the unification of the businesses of KCI, LifeCell and Systagenix under our Acelity brand, designed to allow us to leverage our complementary product portfolio with our sales, marketing and distribution network to improve our go-to-market approach, drive increased market penetration through cross-selling opportunities and improve sales productivity across our platform.

We initiated this transformation in response to trends and challenges impacting our business and the industry in which we operate. We have managed our business in order to take advantage of the growing global market opportunities for our AWT and Regenerative Medicine products, driven by the following key growth drivers:

•

Favorable Global Demographics and Aging Population. The global population aged 65 and older is expected to grow from approximately 610 million people in 2015 to approximately 1.2 billion people by 2035. There is a strong correlation between age and more severe chronic and surgical wounds and increased frequency of hernia and other abdominal wall defects, as well as breast cancer, thus increasing demand for wound care and soft tissue repair products.

•

Greater Incidence of Obesity, Diabetes and Other Chronic Conditions. According to the World Health Organization, worldwide obesity has more than doubled since 1980, and in 2014, more than 1.9 billion adults, 18 years and older, were overweight, 600 million of whom were obese. The number of people with diabetes is expected to rise from 415 million in 2015 to 642 million by 2040. Obesity and diabetes can cause other chronic conditions, such as venous insufficiencies that can impair the healing process. Higher incidence of these chronic conditions and co-morbidities in turn lead to increased incidence and complexity of wounds. Obesity is also a contributing factor to the incidence of abdominal wall defects, driving demand for soft tissue repair products.

•

Increasing Acceptance of Innovative Technologies and Protocols for Complex Wound Treatment. Education and awareness of the benefits of new wound care technologies and proper wound care protocols have increased as medical institutions and professionals look to reduce healthcare costs by decreasing the length of hospital stays and the risk of infection. This expanded acceptance of best practices has resulted in a shift away from traditional lower-technology wound care modalities and increasing demand for advanced wound care treatments backed by clinical and economic evidence.

•

Increasing Awareness of and Demand for Biologics in Complex Soft Tissue Repair Procedures, such as Breast Reconstruction and Abdominal Wall Reconstruction. The increased incidence of breast cancer combined with rising awareness of post-mastectomy treatment options, including the significant psychological benefits of breast reconstruction, have resulted in increasing numbers of patients seeking breast reconstruction following mastectomy or lumpectomy. This is being driven by increasing surgeon awareness of the large body of published clinical data demonstrating better clinical outcomes from using biologic dermal matrices in soft tissue repair procedures.

•

Shift to Advanced Treatment Protocols Outside of the United States. In emerging markets, the incidence of chronic wounds continues to be under-addressed. As the middle class continues to grow in emerging markets, we expect there will be an increased adoption of advanced wound dressings due to access to better healthcare and greater awareness of the cost-effectiveness of advanced wound therapies for chronic wounds. In addition, in certain developed markets in Europe, there is increased momentum to provide healthcare in post-acute settings. As these post-acute settings develop further, we believe there will be increased adoption of advanced devices, including NPWT, and advanced wound dressings. While biologic dermal matrices are largely used in the United States for breast reconstruction and abdominal wall reconstruction procedures, synthetic meshes are currently more widely used outside the United States. As the awareness of benefits of biologic dermal matrices in the markets outside the United States increases, we expect that there will be increased adoption of biologic dermal matrices in soft tissue repair procedures in such markets.

3033

We have also managed our AWT and Regenerative Medicine businesses in light of the following challenges:

• Decreasing Price and Reimbursement Levels. We have experienced downward pressure on price and reimbursement levels for our AWT devices primarily in the United States and Europe both from public and private third-party payers, including government-funded programs such as Medicare. These decreased pricing and reimbursement levels have resulted from a variety of factors, including strategic pricing reductions in exchange for longer-term contracts and other favorable contract terms, healthcare reform, transition of certain direct markets to indirect models using distributors with greater scale, government austerity measures, Medicare’s durable medical equipment competitive bidding program and the impact of the U.S. government’s sequestration.

•

Cost Containment Efforts of Payers. The consolidation of our customers into larger purchasing groups, such as GPOs and IDNs, has increased their negotiating and purchasing power. This trend, in turn, has resulted in increasing pricing pressure on us due to the consolidation of healthcare facilities, purchasing groups and U.S.-based insurance third party payers, pricing concessions and other cost containment efforts, such as competitive bidding processes.


•	Increased Competition. We have faced increased competition due to increased number of entrants into our key markets.

As a result of these market pressures, our overall pricing and reimbursement levels for AWT devices have declined. For the years ended December 31, 2015, 2014 and 2013, we estimate global pricing and reimbursement declines for AWT devices totaled $38.7 million, $80.0 million and $42.6 million, respectively. A component of these declines was the impact associated with Medicare’s durable medical equipment competitive bidding program and the U.S. government’s sequestration, which together reduced Medicare reimbursement by $2.8 million, $25.0 million and $14.8 million for the years ended December 31, 2015, 2014 and 2013, respectively.

~~We expect that~~ Medicare’s competitive bidding program and related price reductions in 2016 will further adversely impact our revenues in 2016 and 2017. Our total 2015 U.S. Medicare revenue was approximately 6.7%, or $124.6 million, of our global revenue. As Ofa ~~this~~result ~~amount,~~of ~~regions~~recent ~~representing approximately $73.5 million in 2015 revenue are subject to an estimated overall~~ price ~~reduction~~reductions ofand ~~approximately~~competitive ~~45%~~bidding ~~based~~activities ~~on fee schedules announced~~ by ~~CMS in 2015, with approximately half of~~ the ~~reduction~~Centers ~~effective~~for inMedicare ~~January 2016,~~ and ~~the~~Medicaid ~~remainder effective in July 2016. In addition~~Services, ~~our~~or ~~2015 revenue from regions subject to Round Two of the competitive bidding program was approximately $43.7 million. In March 2016,~~ CMS ~~announced new single payment amounts~~, ~~which represent average pricing reductions of approximately 13% in these regions, effective July 2016. In April 2016,~~ we ~~were~~expect informed that KCI was not awarded any contracts in the Round Two regions based on a technical disqualification. We plan to engage in discussions with CMS to seek reconsideration of this decision and are also evaluating various alternatives to provide continued patient access to our ~~products~~aggregate in2016 ~~affected regions~~U. ~~Finally,~~S. ~~2015~~Medicare revenue ~~from regions subject~~ to ~~Round~~be ~~One~~reduced ofby ~~the~~approximately ~~competitive bidding program of~~ $~~7.4~~35 million ~~will be subject to pricing changes resulting from the next round of the competitive bidding program~~, ~~which~~as ~~will~~described ~~become effective January 2017~~below.

Of our total 2015 U.S. Medicare revenue, regions representing approximately $73.5 million are subject to estimated price reductions compared to 2015 levels of approximately 46%, with 18% reductions effective January 2016 and additional reductions of approximately 28% effective July 2016. These reductions are based on fee schedules announced by CMS in 2015 as modified by CMS announcements in the second quarter of 2016. In addition, our 2015 revenue from regions subject to Round Two of the competitive bidding program was approximately $43.7 million. In March 2016, CMS announced reimbursement rates in these regions, representing average pricing reductions of approximately 13%, effective July 2016. In April 2016, we were informed that KCI was not awarded direct supplier contracts in the Round Two regions based on a technical disqualification. In light of the CMS decision, we have contracted with a number of suppliers in order to provide continued patient access to our products in 116 out of the 117 Round Two regions. Finally, revenue from regions subject to Round One of the competitive bidding program was $7.4 million for the year ended December 31, 2015. These Round One regions will be subject to pricing changes resulting from the next round of the competitive bidding program, which will become effective January 2017.

As part of our efforts to address such challenges, trends and uncertainties, we have taken the following actions since our acquisition by the Sponsors:

• Realigning our product portfolio and expanding our addressable market by acquiring the Systagenix wound dressings business, successfully executing tuck-in technology acquisitions, such as the ~~SNaP~~SNAP NPWT product portfolio, and divesting our legacy lower growth, lower margin Therapeutic Support System, or TSS, business and SPY Elite System, or SPY, assets.


•	Successfully commercializing new product categories such as incision management, epidermal skin grafting, fat grafting, instillation NPWT, and innovative customer service solutions, including through the launch of iOn Healing mobile application.


•	Investing in our commercial infrastructure by increasing our U.S. sales organization, expanding our distributor relationships in foreign countries and re-aligning our sales organization to better address the needs of our customers.


•	Expanding and deepening our global footprint through the acquisition of Systagenix which is based in the United Kingdom, as well as increasing market development and product introductions in Europe and emerging markets. Since 2011, we have increased our global presence and now market our products in approximately 80 countries.

~~• Implementing a focused franchise model designed to better align our global research and development and marketing functions with our regional sales forces.~~34

31• Implementing a focused franchise model designed to better align our global research and development and marketing functions with our regional sales forces so we develop and commercialize products and solutions well-tailored to the needs of our key customers and care settings across different geographies.

•

Implementing efficiencies in our systems and operations, which continue to drive significant and sustained cost savings. Such cost-savings initiatives consisted of centralizing our international management and our shared service operations into regional hubs in lower cost jurisdictions, integrating acquired businesses into our existing infrastructure, eliminating redundancy within the organization, creating a strategic procurement capability and lowering our costs through the identification of strategic suppliers and negotiation with them of mutually-advantageous contracts reflecting our integrated global purchasing scale and scope.

As a result of our transformation, we have strengthened our business, increased revenue and expanded margins by developing a unified and streamlined global business with product offerings across the continuum of care. These actions enabled us to stabilize our revenues in 2013 and begin to drive AWT revenue increases in 2014 and 2015, despite the pricing pressures in our industry. For the year ended December 31, 2015, global AWT devices volume increased revenue by $105.7 million, compared to an increase of $58.2 million in 2014. In addition, our business optimization and integration efforts have mitigated a considerable portion of the earnings impact relating to pricing headwinds and stranded costs from the sale of the TSS business. Over the past three years, we have realigned our organization following the sale of TSS and the purchase of the Systagenix business, while at the same time investing in commercial infrastructure, global footprint and building our franchise model. We believe these actions have established a solid foundation to support future growth and leverage our infrastructure in an effective and cost efficient manner.

Use of Constant Currency

As exchange rates are an important factor in understanding period-to-period comparisons, we believe in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a constant currency basis as one measure to evaluate our performance. In this quarterly report on Form 10-Q , we calculate constant currency by calculating current-year results using prior-year foreign currency exchange rates. We generally refer to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

3235

Results of Operations

The following table sets forth, for the periods indicated, our results of operations:

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
($ in thousands)	2016			2015			2016			2015
Revenue:
Rental	$	~~170~~175,~~099~~422		$	~~172~~180,~~839~~397		$	345,521		$	353,236
Sales	~~281~~296,~~267~~999			~~271~~281,~~211~~248			578,266			552,459
Total revenue	~~451~~472,~~366~~421			~~444~~461,~~050~~645			923,787			905,695
Rental expenses	7475,~~895~~794			7877,~~178~~869			150,689			156,047
Cost of sales	78,~~579~~118			7375,~~414~~509			156,697			148,923
Gross profit	~~297~~318,~~892~~509			~~292~~308,~~458~~267			616,401			600,725
Selling, general and administrative expenses	~~164~~182,~~444~~194			~~147~~158,~~763~~994			346,638			306,757
Research and development expenses	1314,~~978~~717			14,~~678~~391			28,695			29,069
Acquired intangible asset amortization	4241,~~202~~159			4544,~~877~~712			83,361			90,589
Operating earnings	7780,~~268~~439			8490,~~140~~170			157,707			174,310
Interest income and other	~~107~~589			~~147~~67			696			214
Interest expense	(~~108~~110,~~552~~428		)	(~~104~~107,~~726~~374		)	(218,980		)	(212,100		)
Loss on extinguishment of debt	(310,~~609~~107		)	—			(13,716		)	—
Foreign currency gain (loss)	(48,~~330~~998		)	19(6,~~400~~799		)	4,668			12,601
Derivative instruments loss	(~~682~~357		)	(~~3,348~~919		)	(1,039		)	(4,267		)
Loss before income tax expense (benefit)	(39,798		)	(4,387		)
Loss before income tax benefit	(30,866		)	(24,855		)	(70,664		)	(29,242		)
Income tax expense (benefit)	(13,823		)	144
Income tax benefit	(10,751		)	(7,224		)	(24,574		)	(7,080		)
Net loss	$	(2520,~~975~~115	)	$	(417,~~531~~631	)	$	(46,090	)	$	(22,162	)

3336

Revenue by Operating Segment

The following table sets forth, for the periods indicated, business unit revenue:

	Three months ended March 31,
	Three months ended June 30,
			2016				As		Constant
	2016		(constant		2015		Reported		Currency %
($ in thousands)	(GAAP)		currency)		(GAAP)		% Change		Change(1)
Advanced Wound Therapeutics revenue:
Rental	$	~~170~~175,~~099~~422	$	~~170~~175,~~877~~184	$	~~172~~180,~~839~~397	(12.68	)%	(12.19	)%
Sales	~~168~~179,~~943~~546		~~173~~181,~~610~~837		~~164~~173,~~420~~817		23.83		54.6
Total – Advanced Wound Therapeutics	~~339~~354,~~042~~968		~~344~~357,~~487~~021		~~337~~354,~~259~~214		0.52		20.18
Regenerative Medicine revenue:
Sales	~~109~~114,~~874~~905		~~110~~114,~~172~~932		~~104~~103,~~169~~529		511.50		511.80
Other revenue:
Sales	2,~~450~~548		2,~~594~~719		23,~~622~~902		(634.67	)	(130.13	)
Total consolidated revenue:
Rental	~~170~~175,~~099~~422		~~170~~175,~~877~~184		~~172~~180,~~839~~397		(12.68	)	(12.19	)
Sales	~~281~~296,~~267~~999		~~286~~299,~~376~~488		~~271~~281,~~211~~248		35.76		5.6.5
Total consolidated revenue	$	~~451~~472,~~366~~421	$	~~457~~474,~~253~~672	$	~~444~~461,~~050~~645	12.63	%	32.08	%
	Six months ended June 30,
			2016				As		Constant
	2016		(constant		2015		Reported		Currency %
($ in thousands)	(GAAP)		currency)		(GAAP)		% Change		Change(1)
Advanced Wound Therapeutics revenue:
Rental	$	345,521	$	346,061	$	353,236	(2.2	)%	(2.0	)%
Sales	348,489		355,447		338,237		3.0		5.1
Total – Advanced Wound Therapeutics	694,010		701,508		691,473		0.4		1.5
Regenerative Medicine revenue:
Sales	224,779		225,104		207,698		8.2		8.4
Other revenue:
Sales	4,998		5,313		6,524		(23.4	)	(18.6	)
Total consolidated revenue:
Rental	345,521		346,061		353,236		(2.2	)	(2.0	)
Sales	578,266		585,864		552,459		4.7		6.0
Total consolidated revenue	$	923,787	$	931,925	$	905,695	2.0	%	2.9	%
(1) Represents percentage change between non-GAAP constant currency revenue and GAAP revenue from the prior year.

The following table sets forth, for the periods indicated, the percentage relationship of each item to total revenue in the period, as well as the changes in each line item:

	Three months ended March 31,
	Three months ended June 30,							Six months ended June 30,
	2016		2015		Change			2016		2015		Change
Advanced Wound Therapeutics revenue	75.2	%	76.08	%	(80160	)	bps	75.2	%	76.3	%	(110	)	bps
Regenerative Medicine revenue	24.3	%	2322.54	%	80190		bps	24.3	%	22.9	%	140		bps
Other revenue	0.5	%	0.58	%	—(30	)	bps	0.5	%	0.8	%	(30	)	bps
Total consolidated revenue	100.0	%	100.0	%				100.0	%	100.0	%
Rental revenue	37.71	%	3839.91	%	(~~120~~200	)	bps	37.4	%	39.0	%	(160	)	bps
Sales revenue	62.39	%	6160.19	%	~~120~~200		bps	62.6	%	61.0	%	160		bps
Total consolidated revenue	100.0	%	100.0	%				100.0	%	100.0	%

AWT revenue for the ~~first~~second quarter of 2016 increased $10.8 million, or 0.52%, as reported on a GAAP basis, and $7.2.8 million, or 0.8%, on a constant currency basis, compared to the prior year period. AWT revenue for the first six months of 2016 increased $2.5 million, or 0.4%, as reported on a GAAP basis, and $10.0 million, or 1.5%, on a constant currency basis, compared to the prior year period. The increase in AWT revenue for the second quarter and first six months of 2016 was due primarily to increased volumes in ~~advance~~advanced wound devices and strong Prevena sales., partially offset by a decline in average pricing and decreased revenue from advanced wound dressings in international markets due primarily to timing of distributor ordering patterns. Foreign currency exchange rate movements unfavorably impacted AWT sales revenue by $42.3 million, or 1.3%, and $7.0 million, or 2.81%, for the second quarter and first six months of 2016, respectively, compared to the prior year ~~period~~periods. Excluding the impact of foreign currency exchange rate movements, AWT sales revenue for the ~~first~~second quarter and first six months of 2016 increased $98.0 million, or 4.6%, and $17.2 million, or 5.61%, respectively, compared to the prior year ~~period~~periods due primarily to increased volumes in advanced wound devices, including increased revenue from expansion products ~~and growth internationally~~, partially offset by a decline in average pricing of our advanced wound devices and decreased revenue from advanced wound dressings in international markets due primarily to timing of distributor ordering patterns. Foreign currency exchange rate movements ~~unfavorably~~ impacted AWT rental revenue favorably by $0.82 million, or 0.1%, for the second quarter and unfavorably by $0.5 million, or 0.2%, for the first six months of 2016 compared to the prior year ~~period~~periods. Excluding the impact of the foreign currency exchange rate movements, AWT rental revenue for the ~~first~~second quarter and first six months of 2016 decreased $5.2 million, or 2.09%, or $7.2 million, or 12.10%, respectively, compared to the prior year ~~period~~periods due to lower pricing, partially offset by increased rental volumes. Global AWT devices pricing and reimbursement declined approximately $820.13 million in the ~~first~~second quarter of 2016, compared to the prior year period. Of this decline, approximately $4.9 million related to Medicare’s durable medical equipment competitive bidding program and the U.S. government’s sequestration, which further reduced Medicare pricing.

34Regenerative Medicine revenue for the second quarter of 2016 increased $11.4 million, or 11.0%, on both a reported GAAP basis and on a constant currency basis, compared to the prior year period. Regenerative Medicine revenue for the first six months of 2016 increased $17.1 million, or 8.2%, as reported on a GAAP basis, and $17.4 million, or 8.4%, on a constant currency basis, compared to the prior year period. The increase in our Regenerative Medicine revenue was primarily driven by volume growth associated with an increase in the number of breast reconstruction procedures using our Regenerative Medicine products, strong Revolve sales, and Strattice growth in Europe, partially offset by decreases in the number of procedures using our abdominal wall reconstruction products as some customers continue choosing lower cost synthetic alternatives for less complex procedures.

~~period~~Other revenue for the second quarter of 2016 decreased $1.4 Ofmillion, ~~this~~as ~~decline~~reported on a GAAP basis, ~~approximately~~and $31.52 million, ~~related~~on toa ~~Medicare’s~~constant ~~durable~~currency ~~medical~~basis, ~~equipment~~compared ~~competitive~~to ~~bidding~~the ~~program~~prior ~~and~~year period. Other revenue for the Ufirst six months of 2016 decreased $1.S5 million, as reported on a GAAP basis, and $1.2 ~~government’s~~million, ~~sequestration~~on a constant currency basis, ~~which~~compared ~~further~~to ~~reduced~~the ~~Medicare~~prior ~~pricing~~year period. Other revenue consists of contract manufacturing revenue from our manufacturing plant in Gargrave, England.

Regenerative Medicine revenue for the first quarter of 2016 increased $5.7 million, or 5.5%, as reported on a GAAP basis, and $6.0 million, or 5.8%, on a constant currency basis, compared to the prior year period. The increase in our Regenerative Medicine revenue was primarily driven by volume growth associated with an increase in the number of breast reconstruction procedures using our Regenerative Medicine products and strong Revolve sales, partially offset by decreases in the number of procedures using abdominal wall reconstruction products as some customers continue choosing lower cost synthetic alternatives for less complex procedures. 38

Other revenue for the first quarter of 2016 decreased $0.2 million, as reported on a GAAP basis, and was flat on a constant currency basis, compared to the prior year period. Other revenue consists of contract manufacturing revenue from our manufacturing plant in Gargrave, England.

Gross Profit and Gross Profit Margin

The following table presents the gross profit and gross profit margin (calculated as gross profit divided by total revenue for the periods indicated:

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
($ in thousands)	2016			2015			2016			2015
Gross profit	$	~~297~~318,~~892~~509		$	~~292~~308,~~458~~267		$	616,401		$	600,725
Gross profit margin	6667.04		%	6566.98		%	66.7		%	66.3		%

Gross profit margin increased by 1060 basis points to 6667.04% in the ~~first~~second quarter of 2016 from 6566.98% in the prior year period and increased by 40 basis points to 66.7% in the first six months of 2016 from 66.3% in the prior year period. The increase in the gross profit margin during the ~~first~~second quarter compared to the prior year period was due primarily to lower expenses related to marketing, depreciation and rental fleet maintenance, partially offset by the impact of lower pricing associated with competitive bidding and the expansion of our distributor relationships in foreign countries, which yield lower gross margins. The increase in gross profit margin during the first six months of 2016 compared to the prior year period was ~~primarily~~ due primarily to ~~improved~~lower ~~production~~expenses ~~yields~~related to marketing, ~~primarily~~selling, indepreciation ~~our~~and ~~Regenerative~~rental ~~Medicine~~fleet ~~business~~maintenance, partially offset by the impact of lower pricing associated with competitive bidding and the expansion of our distributor relationships in foreign countries, which yield lower gross margins.

Cost of sales for the ~~first~~second quarter and first six months of 2016 ~~benefited~~increased ~~from~~due ~~improved~~primarily ~~production~~to ~~yields,~~increased ~~primarily~~sales involumes ~~our~~of AWT and Regenerative Medicine ~~business~~products. Foreign currency exchange rate movements favorably impacted cost of sales for the ~~first~~second quarter and first six months of 2016 by $10.47 million and $2.1 million, respectively, compared to the prior year ~~period~~periods.

Rental expense for the ~~first~~second quarter benefited from lower expenses related to depreciation, rental fleet maintenance, and marketing of our rental products. Rental expense for the first six months of 2016 benefited from lower ~~sales-related~~ expenses ~~associated~~related ~~with~~to ~~the~~marketing, ~~decrease~~selling, indepreciation and rental ~~revenue~~fleet maintenance. Foreign currency exchange rate movements also favorably impacted rental expenses for the ~~first~~second quarter and first six months of 2016 by $10.1 million and $1.2 million, respectively, compared to the prior year ~~period~~periods.

Selling, General and Administrative Expenses

The following table presents selling, general and administrative expenses (“SG&A”) and the percentage relationship to total revenue for the periods indicated:

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
($ in thousands)	2016			2015			2016			2015
Selling, general and administrative expenses	$	~~164~~182,~~444~~194		$	~~147~~158,~~763~~994		$	346,638		$	306,757
As a percent of total revenue	3638.46		%	3334.34		%	37.5		%	33.9		%

SG&A expenses increased by $1623.72 million and $39.9 million in the ~~first~~second quarter and first six months of 2016, respectively, compared to the prior year ~~period~~periods. The increase in SG&A expenses for the ~~first~~second quarter and first six months of 2016 was due primarily to investments being made in our focused franchise ~~structure~~model, sales force and marketing to drive sales revenue growth. Additionally, we incurred $6.9 million and $7.5 million of expenses in connection with our debt transactions during the second quarter and first six months of 2016, respectively. These increases were partially offset by foreign currency exchange rate movements which favorably impacted SG&A expenses during the ~~first~~second quarter and first six months of 2016 by $21.61 million and $3.7 million, respectively, compared to the prior year ~~period~~periods.

3539

Research and Development Expenses

The following table presents research and development expenses and the percentage relationship to total revenue for the periods indicated:

	Three months ended March 31,
	Three months ended June 30,						Six months ended June 30,
($ in thousands)	2016			2015			2016			2015
Research and development expenses	$	1314,~~978~~717		$	14,~~678~~391		$	28,695		$	29,069
As a percent of total revenue	3.1		%	3.31		%	3.1		%	3.2		%

The decrease in R&D expenses in the first six months of 2016 is due primarily to lower salary-related expenses due to lower employee headcount. ~~Expenses associated with product development, clinical studies and clinical research also decreased due to savings associated with our integration efforts.~~

Acquired Intangible Asset Amortization

We have recorded identifiable intangible assets in connection with the 2011 LBO, the 2013 Systagenix acquisition and various technology acquisitions. During the ~~first~~second quarters of 2016 and 2015, we recorded $4241.2 million and $4544.97 million, respectively, of amortization expense associated with these identifiable intangible assets. During the first six months of 2016 and 2015, we recorded $83.4 million and $90.6 million, respectively, of amortization expense associated with these identifiable intangible assets.

Interest Expense

Interest expense increased to $~~108~~110.64 million and $219.0 million in the ~~first~~second quarter and first six months of 2016, respectively, compared to $~~104~~107.74 million and $212.1 million in the prior year ~~period~~periods due to higher interest rates associated with our Senior Secured Credit Facilities and the addition of our $7.875% First Lien Senior Secured Notes, resulting in a higher average debt balance. These increases were partially offset by the repayment in full of our Senior Term E-2 Credit Facility. and the non-extended portion of our Senior Dollar Term E-1 Credit Facility, a decrease in the Wake Forest settlement liability accretion due to scheduled payments and lower fees associated with our letters of credit.

Loss on Extinguishment of Debt

During the second quarter and first six months of 2016, we recorded $10.1 million and $13.7 million, respectively, of loss on extinguishment of debt associated with amendments to our Senior Secured Credit Facilities and Revolving Credit Facility. The loss on extinguishment of debt included the write off of net debt issuance costs and unamortized net discount of $5.8 million and $4.3 million, respectively, in the second quarter of 2016 and $7.9 million and $5.8 million, respectively, in the first six months of 2016.

Foreign Currency Gain (Loss)

Foreign currency ~~transaction~~transactions ~~loss~~resulted ~~was~~in gains of $9.0 million and $4.37 million during the ~~first~~second quarter and first six months of 2016, respectively, compared to a ~~gain~~loss of $196.48 million during the ~~first~~second quarter of 2015 and a gain of $12.6 million during the first six months of 2015. The revaluation of the Term ~~E-1~~F ~~EURO~~Euro loan to U.S. dollars represented a foreign currency transaction ~~loss~~gain of $127.3 million during the ~~first~~second quarter of 2016 and a loss of $5.0 million during the first six months of 2016 compared to a loss of $9.5 million and gain of $3223.40 million in the comparable prior year ~~period~~periods. Excluding the revaluation of the Term ~~E-1~~F ~~EURO~~Euro loan to U.S. dollars, we recognized foreign currency exchange gains of $81.07 million and $9.6 million during the ~~first~~second quarter and first six months of 2016, respectively, compared to a ~~loss~~gain of $132.07 million inand ~~the~~loss ~~prior~~of ~~year~~$10.4 ~~period~~million ~~due to significant fluctuations~~ in the ~~Euro~~comparable ~~exchange~~prior ~~rate.~~year periods.

Derivative Instruments Loss

During the ~~first~~second quarter and first six months of 2016, we recorded a derivative instruments loss of $0.74 million and$1.0 million, respectively, due primarily to fluctuations in the value of our interest rate derivative instruments. During the ~~first~~second quarter and first six months of 2015, the derivative instruments loss was $30.9 million and $4.3 million, respectively.

~~Income Tax Expense (Benefit)~~40

~~During~~Income ~~the~~Tax first quarter of 2016, we recorded an income tax benefit of $13.8 million compared to income tax expense of $0.1 million in the comparable prior year period. The income tax benefit was primarily due to higher pretax losses in the first quarter of 2016. Benefit

During the second quarter and first six months of 2016, we recorded an income tax benefit of $10.8 million and $24.6 million, respectively, compared to $7.2 million and $7.1 million, respectively, in the comparable prior year periods. The income tax benefit was primarily due to higher pretax losses in the second quarter and first six months of 2016.

Net Loss

Net loss increased by $212.5 million to $2620.01 million for the ~~first~~second quarter of 2016, compared to $417.56 million in the prior year period. ~~The~~This increase ~~was~~during ~~primarily~~the second quarter was due primarily to the loss on debt extinguishment of $410.31 million and expenses associated with our debt transactions of $6.9 million, partially offset by $9.0 million of foreign currency ~~losses~~gains compared to foreign currency ~~gains~~losses of $196.48 million in the prior year period. Net loss increased by $23.9 million to $46.1 million for the first six months of 2016, compared to $22.2 million in the prior year period. This increase during the first six months of 2016 was due primarily to the loss on debt extinguishment of $13.7 million, expenses associated with our debt transactions of $7.5 million and a decrease in foreign currency gains to $4.7 million compared to $12.6 million in the prior year period. Also contributing to the higher net loss in the ~~first~~second quarter and first six months of 2016 were the increased investments made in our focused franchise ~~structure~~model, sales force and marketing to drive growth, partially offset by revenue growth and expense savings associated with our integration and business optimization efforts.

LIQUIDITY AND CAPITAL RESOURCES

Our primary uses of cash are working capital requirements, capital expenditures and debt service requirements. Additionally, from time to time, we may use capital for acquisitions and other investing and financing activities. Working capital is required principally to finance accounts receivable and inventory. Our working capital requirements vary from period-to-period depending on manufacturing volumes, the timing of shipments and the payment cycles of our customers and payers. Our capital expenditures consist primarily of manufactured rental assets, manufacturing equipment, computer hardware and software, expenditures related to leasehold improvements and expenditures related to our global corporate headquarters building.

Historically, our primary source of liquidity has been cash flow from operations. In addition, we also have a $200.0 million Revolving Credit Facility to provide us with an additional source of liquidity. We anticipate that cash generated from operations together with amounts available under our Revolving Credit Facility will be sufficient to meet our future working capital requirements, capital expenditures and debt service obligations as they become due for the foreseeable future. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings or a combination of these potential sources of funds. In the event that we need access to additional cash, we may not be able to access the credit markets on commercially acceptable terms or at all. Our ability to fund future operating expenses and capital expenditures and our ability to meet future debt service obligations or refinance our indebtedness will depend on our future operating performance which will be affected by general economic, financial and other factors beyond our control, including those described under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

As of ~~March~~June 3130, 2016, our cash and cash equivalents were $~~223~~99.62 million. We are highly leveraged. As of ~~March~~June 3130, 2016, we had approximately $4.89 billion of aggregate principal amount of indebtedness outstanding, with an additional $~~162~~138.14 million of unused commitments available to be borrowed under our Revolving Credit Facility. We also can incur additional indebtedness, including secured indebtedness, if certain specified conditions are met under the credit agreement governing the Senior Secured Credit Facilities and the indentures governing the outstanding notes. Our liquidity requirements will be significant, primarily due to debt service requirements.

We and our Sponsors may from time to time seek to retire or purchase our outstanding debt through cash purchases, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

Cash Flows

The following table summarizes the net cash provided (used) by operating activities, investing activities and financing activities for the periods indicated:

	Three months ended March 31,
	Six months ended June 30,
($ in thousands)	2016			2015
Net cash provided by operating activities	$	78,185		$	102,951
Net cash used by operating activities	$	(39,579	)	$	(4,004	)
Net cash used by investing activities	(1939,~~577~~542		)	(1540,~~668~~312		)
Net cash provided (used) by financing activities	73,645			(13,243		)
Net cash provided by financing activities	88,349			6,952
Effect of exchange rate changes on cash and cash equivalents	21,~~954~~560			(75,~~072~~025		)
Net increase in cash and cash equivalents	$	135,207		$	66,968
Net increase (decrease) in cash and cash equivalents	$	10,788		$	(42,389	)

Operating Activities

For the first ~~quarter~~six months of 2016, net cash ~~provided~~used by operating activities was $7839.26 million, compared to ~~net cash provided by operating activities of~~ $~~103~~4.0 million for the first ~~quarter~~six months of 2015. The ~~decrease~~increase in cash ~~provided~~used by operations was primarily driven by lower operating earnings and higher working capital requirements, which was due primarily to revenue growth and an increase in average payment terms associated with the expansion of our distributor program in foreign markets.

Investing Activities

For the first ~~quarter~~six months of 2016, net cash used by investing activities was $1939.65 million, compared to $1540.73 million for the first ~~quarter~~six months of 2015. Net cash used by investing activities was ~~higher~~lower during the first ~~quarter~~six months of 2016 due to business acquisition activities during 2015, partially offset by higher capital expenditures during 2016.

Financing Activities

For the first ~~quarter~~six months of 2016, net cash provided by financing activities was $7388.63 million, compared to ~~net cash used by financing activities of~~ $137.20 million for the first ~~quarter~~six months of 2015. Net cash provided by financing activities increased primarily due to the proceeds from the issuance of ~~$400.0 million aggregate principal amount of~~ 7.875% First Lien Senior Secured Notes, net of the repayment of all amounts outstanding under our Senior Term E-2 Credit Facility and the non-extended portion of our Senior Dollar Term E-1 Credit Facility.

Capital Expenditures

During the first ~~quarters~~six months of 2016 and 2015, we made capital expenditures of $1735.58 million and $1029.56 million, respectively. Capital expenditures during the first ~~quarters~~six months of 2016 and 2015 related primarily to expanding the rental fleet and information technology projects and purchases.

Debt

Senior Secured Credit Facilities

On November 4, 2011, Kinetic Concepts, Inc. and its subsidiary, KCI USA, Inc., as co-borrowers, or collectively, the Borrowers, Acelity L.P. Inc., Chiron Holdings, Inc. and Chiron Topco, Inc. and, with respect to certain representations and warranties, Chiron Guernsey GP Co. Limited, entered into a credit agreement, or the Senior Secured Credit Facilities, with Bank of America, N.A., as administrative and collateral agent, Morgan Stanley Senior Funding, Inc. and Credit Suisse Securities (USA) LLC, as syndication agents, Royal Bank of Canada, as documentation agent, UBS Securities LLC, as co-manager, Bank of America, N.A., Morgan Stanley Senior Funding, Inc., Credit Suisse Securities (USA) LLC and RBC Capital Markets, LLC, as joint lead arrangers and bookrunners, and the lenders party thereto from time to time. The Senior Secured Credit Facilities were amended on November 7, 2012, June 14, 2013, October 28, 2013, November 15, 2013, January 22, 2014, and March 10, 2015, to, among other things, reduce the overall pricing and amend the financial covenants of the Senior Secured Credit Facilities. The Senior Secured Credit Facilities were ~~also~~ amended on February 9, 2016, to, among other things, extend the maturity date of certain lenders’ commitments under the Revolving Credit Facility. After giving effect to the February 2016 amendments, we continue to have $200 million of aggregate revolving loan commitments under our Revolving Credit Facility with $28.7 million of the commitments maturing on November 4, 2016, and $171.3 million maturing on November 4, 2017. The Senior Secured Credit Facilities were

The following table sets forth the amounts owed under the Senior Secured Credit Facilities, the effective interest rates on such outstanding amounts, and the amount available for additional borrowing thereunder, as of March 31, 2016 (dollars in thousands):42

Senior Secured Credit Facilities	MaturityDate		EffectiveInterestRate			AmountOutstanding (1)		Amount Availablefor AdditionalBorrowing
Senior Revolving Credit Facility	November 2016November 2017	(2)	—	%		$	—	$	162,061	(2)(3)
Senior Dollar Term E-1 Credit Facility	May 2018		5.00	%	(4)	1,884,237		—
Senior Euro Term E-1 Credit Facility	May 2018		5.67	%	(4)	267,865		—
Total						$	2,152,102	$	162,061

also amended on June 16, 2016 to, among other things, create new classes of Dollar Term F Loans and Euro Term F Loans, having the same rights and obligations as the Dollar Term E-1 Loans and Euro Term E-1 Loans as set forth in the Senior Secured Credit Facilities, except as revised by the amendment. Lenders exchanged $1.707 billion of Dollar Term E-1 Loans and all Euro Term E-1 Loans for equivalent amounts of Dollar F Loans and Euro Term F Loans, respectively. The remaining Dollar Term E-1 Loans were repaid with the proceeds from the issuance of First Lien Notes in June 2016. The Dollar Term F Loans and Euro Term F Loans mature on November 4, 2020.

~~(1)~~The ~~Amount~~following table sets forth the amounts owed under the Senior Secured Credit Facilities, the effective interest rates on such outstanding ~~includes~~amounts, and the ~~original~~amount ~~issue~~available ~~discount.~~for additional borrowing thereunder, as of June 30, 2016 (dollars in thousands):



Senior Secured Credit Facilities	Maturity Date		Effective Interest Rate			Amount Outstanding⁽¹⁾		Amount Available for Additional Borrowing
Senior Revolving Credit Facility	November 2016 November 2017	⁽²⁾	6.38	%		$	25,000	$	138,359	⁽²⁾⁽³⁾
Senior Dollar Term F Credit Facility	November 2020		5.26	%	⁽⁴⁾	1,686,047		—
Senior Euro Term F Credit Facility	November 2020		5.49	%	⁽⁴⁾	259,701		—
Total						$	1,970,748	$	138,359

_____________________


(1)	Amount outstanding includes the original issue discount, if applicable.


(2)	After giving effect to Amendment No. 7 and Amendment No. 8, we have aggregate revolving loan commitments under the Revolving Credit Facility of $171.3 million maturing on November 4, 2017, with an additional $28.7 million in revolving loan commitments continuing to mature on November 4, 2016.

(3) At ~~March~~June 3130, 2016, the amount available under the Revolving Credit Facility reflected a reduction of $3736.96 million of letters of credit issued by banks which are party to the Senior Secured Credit Facilities. In addition, we have $75.78 million of letters of credit issued by a bank not party to the Senior Secured Credit Facilities. The $25.0 million borrowing under the Revolving Credit Facility was repaid in July 2016 using cash from operations.

(4) The effective interest rate includes the effect of the original issue discount. Excluding the original issue discount, our nominal interest rate as of ~~March~~June 3130, 2016 was 45.5000% on the Senior Dollar Term ~~E-1~~F Credit Facility and 45.7500% on the Senior Euro Term ~~E-1~~F Credit Facility.

10.5% Second Lien Senior Secured Notes and 12.5% Senior Unsecured Notes

In connection with the 2011 LBO, on November 4, 2011, Kinetic Concepts, Inc. and its subsidiary, KCI USA, Inc., or collectively, the ~~Existing~~ Notes Issuers, co-issued $1.750 billion aggregate principal amount of 10.5% Second Lien Senior Secured Notes due 2018, or the Second Lien Notes, and $750.0 million aggregate principal amount of 12.5% Senior Unsecured Notes due 2019, or the Unsecured Notes.

As of ~~March~~June 3130, 2016, we had outstanding $1,~~735~~736.57 million aggregate principal amount, net of discount of $1413.53 million (net of accretion), of the Second Lien Notes and $~~609~~610.90 million aggregate principal amount, net of discount of $2.10 million (net of accretion), of the Unsecured Notes.

Interest on the Second Lien Notes accrues at the rate of 10.50% per annum and is payable semi-annually in cash on each May 1 and November 1 to the persons who are registered holders at the close of business on April 15 and October 15 immediately preceding the applicable interest payment date. The Second Lien Notes were issued at a discount resulting in an effective interest rate of 10.87%.

Interest on the Unsecured Notes accrues at the rate of 12.50% per annum and is payable semi-annually in cash on each May 1 and November 1 to the persons who are registered holders at the close of business on April 15 and October 15 immediately preceding the applicable interest payment date. The Unsecured Notes were issued at a discount resulting in an effective interest rate of 12.62%.

7.875% First Lien Senior Secured Notes

On February 9, 2016, the ~~Existing~~ Notes Issuers co-issued $400.0 million aggregate principal amount of 7.875% First Lien Senior Secured Notes due 2021, or the First Lien Notes. On June 22, 2016, the Notes Issuers co-issued an additional $190.0 million aggregate principal amount of First Lien Notes. Interest on the First Lien Notes accrues at the rate of 7.875% per annum and is payable semi-annually in arrears on each February 15 and August 15, beginning on August 15, 2016, to the persons who are registered holders at the close of business on February 1 and August 1 immediately preceding the applicable interest payment date. The First Lien Notes issued on February 9, 2016 were issued at par and the First Lien Notes issued on June 22, 2016 were issued at a premium to par. These First Lien Notes have an effective interest rate of 7.45%. The First Lien Notes are fully and unconditionally guaranteed, jointly and severally, on a senior secured basis, by Acelity L.P. Inc., Chiron Topco, Inc., Chiron Holdings, Inc., LifeCell Corporation and each of Acelity L.P. Inc.’s other subsidiaries to the extent such entities guarantee indebtedness under the Senior Secured Credit Facilities or the Second Lien Notes and Unsecured Notes. The First Lien Notes and related guarantees are initially secured on a first-priority basis by security interests in all of the ~~Existing~~ Notes Issuers’ and the guarantors’ assets that secure our Senior Secured Credit Facilities on a first-priority basis. The First Lien Notes and related guarantees will not be registered for resale under the Securities Act of 1993, as amended, or the Securities Act, or the securities laws of any other jurisdiction or offered to be exchanged for registered notes under the Securities Act or securities laws of any other jurisdiction. On or after February 15, 2018, the ~~Existing~~ Notes Issuers may redeem some or all of the First Lien Notes at redemption prices (expressed as percentages of the principal amount) equal to 103.938% through February 14, 2019, 101.969% from February 15, 2019 through February 14, 2020, and at par thereafter, plus accrued and unpaid interest, if any, to the redemption date.

Covenants

The credit agreement governing the Senior Secured Credit Facilities and the indentures governing the First Lien Notes, Second Lien Notes and Unsecured Notes contain a number of covenants that, among other things, restrict, subject to certain exceptions, our ability to incur or guarantee additional indebtedness; create liens on assets; engage in mergers and consolidations; sell assets; pay dividends and distributions or repurchase capital stock; repay subordinated indebtedness; engage in certain transactions with affiliates; make investments, loans or advances; make certain acquisitions; and in the case of the credit agreement governing the Senior Secured Credit Facilities, change our lines of business. The credit agreement governing the Senior Secured Credit Facilities and the indentures governing the First Lien Notes, Second Lien Notes and Unsecured Notes also contain change of control provisions and certain customary covenants and events of default.

As of ~~March~~June 3130, 2016, we were in compliance with all covenants under the credit agreement governing the Senior Secured Credit Facilities and the indentures governing the ~~Existing~~First Lien Notes, ~~and~~Second ~~the~~Lien ~~First~~Notes ~~Lien~~and Unsecured Notes.

For further information on our long-term debt, see Note 4 of the notes to the condensed consolidated financial statements included herein and Note 5 of the notes to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

Interest Rate Protection

At ~~March~~June 3130, 2016, and December 31, 2015, we were party to three interest rate swap agreements to convert $1.~~378~~376 billion and $1.380 billion, respectively, of our outstanding variable -rate debt to a fixed -rate basis. The aggregate notional amount ~~of the interest rate swaps~~ decreases quarterly by ~~amounts ranging from~~ $1.7 million ~~to $1.8 million~~ until maturity. As of ~~March~~June 3130, 2016, these interest rate protection agreements have not been designated as hedging instruments, and as such, we recognize the fair value of these instruments as an asset or liability with income or expense recognized in the current period.

In April 2016, we entered into three additional interest rate swap agreements to convert $1.165 billion of our variable-rate debt to a fixed-rate basis, which ~~become~~begin ~~effective~~ in December 2016 and extend through December 2021. These agreements have been designated as cash flow hedge instruments. Quarterly payments under the interest rate swap agreements are due on the last day of March, June, September and December. The aggregate notional amount decreases quarterly by amounts ranging from $4.4 million to $84.5 million until maturity.

For further information on our interest rate protection agreements, see Note 5 of the notes to the condensed consolidated financial statements.

Contractual Obligations

~~There~~On ~~have~~February 9, ~~been~~2016, nowe ~~material~~entered ~~changes~~into Amendment No. 7 to the Senior Secured Credit Facilities ("Amendment No. 7"). Pursuant to Amendment No. 7, ~~outside~~among other things, the maturity date of certain consenting lenders’ commitments under the ~~ordinary~~Revolving ~~course~~Credit Facility was extended to November 4, 2017. Promptly after the effectiveness of ~~business~~Amendment No. 7, we permanently reduced, or the Permanent Reduction, a portion of the commitments under our Revolving Credit Facility of lenders that did not consent to extend the maturity date of their commitments under the Revolving Credit Facility pursuant to Amendment No. 7. On February 9, 2016, we also entered into Amendment No. 8 to the Senior Secured Credit Facilities ("Amendment No. 8"). In connection with Amendment No. 8, certain lenders agreed to provide incremental commitments under the Revolving Credit Facility in a principal amount equal to the principal amount of the commitments subject to the Permanent Reduction, and such incremental commitments also have a maturity date of November 4, 2017. After giving effect to Amendment No. 7 and Amendment No. 8, we have aggregate revolving loan commitments under our ~~outstanding~~Revolving ~~contractual~~Credit ~~obligations~~Facility ~~since~~of ~~December~~$171.3 million maturing on November 4, 2017, with an additional $28.7 million in revolving loan commitments continuing to mature on November 4, 2016. On February 319, ~~2015~~2016, the Notes Issuers, co-issued $400.0 million aggregate principal amount of First Lien Senior Secured notes and used the net proceeds to pay in full all amounts outstanding under the Senior Term E-2 Credit Facility.

The following table summarizes our contractual cash obligations for long-term debt and related interest as of June 30, 2016, for each of the periods indicated ($ in thousands):



	2016⁽¹⁾		2017-2018		2019-2020		Thereafter		Total
Long-term debt obligations⁽²⁾	$	13,445	$	1,810,863	$	2,530,072	$	590,000	$	4,944,380
Interest on long-term debt obligations⁽²⁾	$	204,967	$	810,922	$	345,189	$	23,231	$	1,384,309

(1) Amounts represent estimated payments due for the last six months of 2016.

(2) Amounts and timing may be different from our estimated payments due to potential voluntary prepayments, borrowings, interest rate fluctuations and foreign currency exchange rate fluctuations.

Other than Amendment No. 7, Amendment No. 8, Amendment No. 9, the issuance of First Lien Notes and the repayment of Term E-1 and Term E-2 loans with the proceeds therefrom, there have been no material changes, outside of the ordinary course of business, in our outstanding contractual obligations since December 31, 2015.

Critical Accounting Estimates

For a description of our critical accounting estimates, please see our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 under the heading Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Estimates."

Recently Issued Accounting Standards

See note 1(e) of the notes to condensed consolidated financial statements included in this report for a discussion of recently issued accounting standards.

4045

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to various market risks, including fluctuations in interest rates and variability in currency exchange rates. There have been no material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015. For a description of our policies, procedures and internal processes governing our management of market risk and the use of financial instruments to manage our exposure to such risk, please see our Annual Report for the fiscal year ended December 31, 2015 under the heading “Quantitative and Qualitative Disclosures About Market Risk.”

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures. Our management, with the participation of the principal executive officer and our principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting. There have not been any changes in our internal control over financial reporting (as such term is defined by paragraph (f) of Rule 13a-15) under the Exchange Act, during the ~~first~~second fiscal quarter of 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Incorporated in this Item 1, by reference, are the legal proceedings described in Note 7 of the notes to condensed consolidated financial statements included in this report under the heading "Commitments and Contingencies: Legal Proceedings."

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

4146

ITEM 6. EXHIBITS

A list of all exhibits filed or included as part of this quarterly report on Form 10-Q is as follows:
Exhibit Number	Description
3.1	Declaration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on October 1, 2012).
3.2	Certificate of Registration of Acelity L.P. Inc. (filed as Exhibit 3.2 to our Form 10-Q for the quarterly period ended September 30, 2014).
3.3	Third Amended and Restated Limited Partnership Agreement of Acelity L.P. Inc. (filed as Exhibit 3.3 to our Form 10-Q for the quarterly period ended September 30, 2014).
4.1	Indenture, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., the guarantors party thereto and Wilmington Trust, N.A., as trustee and as collateral agent (filed as Exhibit 4.1 to our Form 8-K filed on February 10, 2016).
4.2	~~Form~~Global ofNotes representing 7.875% First Lien Senior Secured Notes due 2021 (~~included~~filed as Exhibit A4.2 to ~~Exhibit~~our ~~4.1~~Form 8-K filed on June 22, 2016).
10.1	Amendment No. 7 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.1 to our Form 8-K filed on February 10, 2016).
4.3	Officer’s Certificate, dated June 22, 2016 (filed as Exhibit 4.3 to our Form 8-K filed on June 22, 2016).
10.2	Amendment No. 8 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.2 to our Form 8-K filed on February 10, 2016).
10.1	Amendment No. 9 to the Credit Agreement, dated as of June 16, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.1 to our Form 8-K filed on June 17, 2016).
*†10.3	Third Amended and Restated Chiron Guernsey Holdings L.P. Inc. Executive Equity Incentive Plan.
†31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated August 2, 2016.
†31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated August 2, 2016.
†31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated August 2, 2016.
†32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†100	Interactive data files.
	† Exhibit filed herewith.
	* Compensatory arrangements for director(s) and/or executive officer(s).

4247

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Antonio, State of Texas on ~~May~~August 32, 2016.

	ACELITY L.P. INC.
	(REGISTRANT)
Date: May 3, 2016	By:	/s/ Joseph F. Woody
Date: August 2, 2016	By:	/s/ Joseph F. Woody
		Joseph F. Woody
		Principal Executive Officer
		(Duly Authorized Officer)
Date: May 3, 2016	By:	/s/ Thomas W. Casey
Date: August 2, 2016	By:	/s/ Thomas W. Casey
		Thomas W. Casey
		Principal Financial Officer
		(Duly Authorized Officer)

4348

EXHIBITS

Exhibit Number	Description
3.1	Declaration of Centaur Guernsey L.P. Inc. (filed as Exhibit 3.3 to our Registration Statement on Form S-4 filed on October 1, 2012).
3.2	Certificate of Registration of Acelity L.P. Inc. (filed as Exhibit 3.2 to our Form 10-Q for the quarterly period ended September 30, 2014).
3.3	Third Amended and Restated Limited Partnership Agreement of Acelity L.P. Inc. (filed as Exhibit 3.3 to our Form 10-Q for the quarterly period ended September 30, 2014).
4.1	Indenture, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., the guarantors party thereto and Wilmington Trust, N.A., as trustee and as collateral agent (filed as Exhibit 4.1 to our Form 8-K filed on February 10, 2016).
4.2	~~Form~~Global ofNotes representing 7.875% First Lien Senior Secured Notes due 2021 (~~included~~filed as Exhibit A4.2 to ~~Exhibit~~our ~~4.1~~Form 8-K filed on June 22, 2016).
10.1	Amendment No. 7 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.1 to our Form 8-K filed on February 10, 2016).
4.3	Officer’s Certificate, dated June 22, 2016 (filed as Exhibit 4.3 to our Form 8-K filed on June 22, 2016).
10.2	Amendment No. 8 to the Credit Agreement, dated as of February 9, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.2 to our Form 8-K filed on February 10, 2016).
10.1	Amendment No. 9 to the Credit Agreement, dated as of June 16, 2016, by and among Kinetic Concepts, Inc., KCI USA, Inc., Chiron Guernsey GP Co. Limited, the guarantors party thereto, the lenders party thereto, and Bank of America, N.A., as Administrative Agent for the lenders (filed as Exhibit 10.1 to our Form 8-K filed on June 17, 2016).
*†10.3	Third Amended and Restated Chiron Guernsey Holdings L.P. Inc. Executive Equity Incentive Plan.
†31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated August 2, 2016.
†31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated August 2, 2016.
†31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated August 2, 2016.
†32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 dated May 3, 2016.
†100	Interactive data files.
	† Exhibit filed herewith.
	* Compensatory arrangements for director(s) and/or executive officer(s).

4449

Filing Compare · Acelity L.P. Inc.